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 We conducted two fMRI studies assessing the relationship between psychopathy and 
drug- and food-related neural reactivity. In the first study, we assessed the relationship between 
psychopathic traits and neural reactivity among 47 cocaine-dependent and 58 non-dependent 
participants. The cocaine-dependent group exhibited a neural processing bias towards drug-
related stimuli within a corticolimbic circuit involved in decision-making, salience attribution, 
and motivation. Psychopathic traits both sensitized this neural processing bias and modulated the 
effect of substance use severity. In the second study, we separated dependent participants into 
psychologically- (n =25) or physiologically-dependent (n = 20) participants and observed a 
neural processing bias towards drug-related stimuli among physiologically-dependent 
participants alone. Interestingly, both psychopathic traits and substance use severity exhibited 
positive correlations to drug > food reactivity within psychologically-dependent participants. 
These results further our understanding of the comorbidity between psychopathy and addiction 
and help conceptualize a new comprehensive model for the development of addiction. 
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According to the 2016 World Drug Report from the United Nations Office on Drugs and 
Crime (UNODC), 5.2% of the world’s population used illicit substances in 2014, with 0.6% 
demonstrating drug use problems (UNODC, 2016). Moreover, the most-recent statistics on a 
current global opioid-use epidemic reported a 900% increase in the number of individuals with 
an opioid addiction seeking treatment, and a 171% increase in the number of heroin-related 
overdoses and deaths in the preceding 15 years (Kolodny et al., 2015). The problem was equally 
concerning in Canada according to the 2012 Canadian Community Health Survey (Statistics 
Canada, 2012), where lifetime diagnoses of substance use disorders (SUDs) were prevalent at 
21.6%, and 4.4% when assessing diagnostic criteria in the preceding 12 months.  
These prevalence rates increased in Canadian antisocial populations, with 70% of 
offenders reporting substance use and abuse during the year prior to their incarceration 
(Canadian Centre on Substance Abuse [CCSA], 2004). Moreover, 50 – 90% of offenders had a 
SUD, with 51% of offenders exhibiting alcohol use disorders and 48% exhibiting SUDs other 
than alcohol (CCSA, 2004), and 4.3% of reported offences were drug related offences in 2012 
(Public Safety Canada, 2013). Furthermore, substance use was considered one of the Central 
Eight Risk Factors for criminal behaviour according to Andrews and Bonta (2006) and was an 
item on widely used risk assessment instruments for violence and recidivism, such as the 
Historical-Clinical-Risk Management scale (HCR-20; Webster, Douglas, E1aves, & Hart, 1997) 
and the Violence Risk Appraisal Guide (VRAG; Quinsey, Harris, Rice, & Cormier, 1998).  
 




The economic impact of these substance abuse problems is staggering. In 2002, substance 
use problems had a cost the Canadian economy $39.8 billion, with substance-use-related law 
enforcement costs accounting for $3.33 billion dollars; substance-use-related court costs 
accounting for $843 million dollars; and substance-use-related correctional costs accounting for 
$1.23 billion dollars (CCSA, 2006).  
 Another disorder that exhibited a greater prevalence among antisocial populations is 
psychopathic personality disorder, with a prevalence of roughly 12%-21% of the prison 
population (Hare, 2003; Hart & Hare, 1989), a higher percentage when compared to the 
community population’s prevalence of roughly 1% (Coid, Yang, Ullrich, Roberts & Hare, 2009; 
Neumann & Hare, 2008). Psychopathic traits were also considered predisposition for violent 
criminal behaviour on the VRAG (Quinsey et al., 1998) and are also positively correlated with 
scores on the HCR-20 (Neves et al., 2011).  
These disorders have been found to share several common risk factors. For instance, 
psychopaths have been reported as impulsive (Andershed, Kerr, Statin, & Levander, 2002; Dean 
et al., 2013; Hare, 2003; Levenson, Kent, & Fitzpatrick, 1995; Lilienfeld & Fowler, 2006; 
Morgan, Gray, & Snowden, 2011), irresponsible (Hare, 2003; Andershed et al., 2002), and have 
demonstrated a strong inclination towards making risky decisions, (Mitchell, Colledge, Leonard, 
& Blair, 2002; Vassileva et al., 2007; Beszterczey, Nestor, Shirai, & Harding, 2013; Hosker-
Field, Molnar, & Book, 2016; Swogger, Walsh, Lejuez, & Kosson, 2010). Psychopathic 
individuals have also been commonly considered sensation seekers with a high sensitivity for 
rewarding stimuli (Haapasalo, 1990; Hare, 2003; Hopley & Brunelle, 2012). These 
characteristics have also been noted as predictors of SUDs (Koob & Volkow, 2010; Woicik, 
Stewart, Pihl, & Conrod, 2009), with impulsivity (Bernstein et al., 2015; Coskunpinar & Cyders, 




2013; Leeman, Hoff, Krishnan-Sarin, Patock-Peckham, & Potenza, 2014; Leung et al., 2017; 
Rodríguez-Cintas et al., 2016; Shin, Chung & Jeon, 2013), sensation seeking (Horvath, Milich, 
Lynam, Leukefeld, & Clayton, 2004; Leeman et al., 2014; Shin et al., 2013; Stautz & Cooper, 
2013), reward sensitivity (Dissabandara et al., 2014; Franken, Muris, & Georgieva, 2006; 
Murphy, Murphy, & Garavan, 2014), and risky-decision-making (Ekhtiari, Victor, & Paulus, 
2017; Kim-Spoon et al., 2016) being associated with substance use frequency and the incidence 
of substance dependence.  
 However, the comorbidity between these two disorders remains rather controversial, 
particularly due to a disconnect between psychometric/behavioral empirical studies and 
neuroimaging studies. To reconcile these two camps of research, I have conducted two studies 
that further investigated the relationship between psychopathic traits and neurocognitive 
abnormalities apparent in addiction (i.e. neural processing of drug-related stimuli). Before 
presenting this research, a thorough background review will be provided. This review will be 
organized in the following way: first, I will be presenting definitions of addiction and 
psychopathic personality disorder, with a primary emphasis on theoretical models of these 
disorders that this research will be specifically testing. Next, I will review studies on the 
comorbidity between addiction and psychopathy, followed by an overview of the relationship 
between psychopathy and the neural processing of drug-related stimuli, which will include a 
discussion on the implication of such a relationship, as well as limitations of this field of 
research. Finally, I will outline how this thesis attempts to reconcile these limitations and further 
our understanding of addiction, and the psychopathy-addiction comorbidity.  
 
 




 Defining addiction 
 According to the fifth and most recent edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5; American Psychiatric Association [APA], 2013), SUDs consist of 
the continued use of a substance despite negative consequences on one’s biopsychosocial health. 
This can include disruptions of one’s social, recreational and occupational responsibilities; be 
associated with problems and dysfunctions in one’s personal life and interpersonal relationships; 
and may or may not be associated with physiological reactions to drug use, including tolerance to 
the drug’s effects and withdrawal symptoms following cessation of use.  
One must have met the threshold for two of the 11 DSM criteria for SUDs to be 
diagnosed with a SUD. These criteria consist of a combination of criteria used to characterize 
two subcategories of SUDs that were diagnosed as separate disorders in the revised fourth 
edition of the DSM (DSM-IV-TR; APA, 2000). One of these categories, assumed to be the more 
severe SUD, is substance dependence, characterized by a continuous maladaptive pattern of 
substance use that persists despite aversive consequences on one’s biopsychosocial health and a 
growing inability to cease use and resort to other sources of reward to satiate one’s hedonic 
needs. It is diagnosed according to seven of the 11 criteria of SUDs, and this diagnostic scheme 
also contains two specifiers, tolerance and withdrawal, which specify whether the participant 
meets the threshold for substance dependence with a physiological (i.e. meets threshold for 
tolerance and withdrawal) or psychological dependence (i.e. important obligations are disrupted, 
and use is persistent, however there are no physiological signs of dependence). If the patient did 
not meet threshold for substance dependence, the interviewer must then proceed to examine the 
other subcategory of SUD: substance abuse, characterized by the continued use of a substance 
accompanied by legal problems and disruptions of social and occupational obligations. 














1. The substance is often taken in larger amounts over 
a longer period than intended 
X  X 
2. There is a persistent desire or unsuccessful efforts 
to cut down or control substance use 
X  X 
3. A great deal of time is spent in activities necessary 
to obtain the substance, use the substance, or 
recover from its effects 
X  X 
4. Craving, or a strong desire or urge to use alcohol X   
5. Continued use despite having persistent or recurrent 
social or interpersonal problems caused or 
exacerbated by the effects of the drug.  
X   
6. Important social, occupational, or recreational 
activities are given up or reduced because of 
substance use. 
X X X 
7. Recurrent use in situations in which it is physically 
hazardous 
X X  
8. The substance use is continued despite knowledge 
of having a persistent physical or psychological 
problem that is likely to have been caused or 
exacerbated by the substance 
X  X 
      9. Tolerance defined by either of the following: 
 a) A need for markedly increased amounts of the 
 substance to achieve intoxication or the desired 
 effect 
 b) Markedly diminished effect with continued use 
 of the same amount of the substance 
X  X 
     10. Withdrawal manifested by either of the following: 
 a) The characteristic withdrawal syndrome for the 
 substance 
 b) The same substance is taken to relieve or avoid 
 withdrawal symptoms 
X  X 
     11. Recurrent drug-related legal problems  X  
Note. SUD = Substance use disorder (according to DSM-5[APA, 2013] criteria); SA = Substance 
abuse disorder (according to DSM-IV-TR [APA, 2000] criteria); SD = Substance dependence 








The decision to combine abuse and dependence into a single category for the DSM-5 
stems from item-response theory analyses (i.e. confirmatory principal component analyses) that 
demonstrated a single latent construct of all DSM abuse/dependence items (Saha et al., 2012). In 
addition, the separation of substance abuse and dependence was criticized for having similarities 
in severity and real-world impact (Schuckit & Smith, 2001; Schuckit, Smith, & Landi, 2000). 
However, DSM-5 SUD-assessments have been associated with inflated diagnostic rates of SUDs 
and false positives (Goldstein et al., 2015; Peer et al., 2013). These inflated diagnostic rates may 
have been due to the combination of abuse and dependence and a lower threshold to attain a 
diagnosis (2/11 criteria to meet threshold for a SUD compared to three of the seven criteria for 
meet threshold for substance dependence; APA, 2000, 2013). In addition, DSM-5 SUD diagnosis 
added a new symptom that was not included into the diagnosis of neither substance dependence 
nor substance abuse: craving (APA, 2013), whom Agrawal, Heath, and Lynskey (2011) 
demonstrated that many interviewees endorsed this craving symptom, which may explain the 
inflated SUD diagnostic rates. This is not to say that the DSM-IV-TR criteria did not have 
criticisms beyond the distinction of substance dependence and substance abuse, as the criteria for 
substance dependence has been criticized for redundancy, excessive focus on use in 
inappropriate situations and contexts, high false positive rates, and poor to modest construct and 
predictive validity (DiFranza et al., 2010; Hasin et al., 2003; Hendricks, Prochaska, Humfleet, & 
Hall, 2008; Widiger & Smith, 1994).  
However, the distinction between physiological and psychological substance dependence 
may hold incremental value. While the DSM-5 no longer utilizes this specifier, many have called 
for the importance in separating DSM-5 SUD diagnoses from physiological substance 
dependence (Blanco, Wall, Okuda, Wang, Iza, & Olfson, 2017). Such a position was related to 




the fact that there is unanimous consensus that physiologically-dependent individuals exhibited 
more addiction-related behavioral patterns relative to psychologically-dependent individuals, 
including more severe drug use patterns, higher relapse rates, and a greater number of 
psychiatric, psychosocial and health-related problems (Lejoyeux, Claudon, McLoughlin, & 
Adès, 2001; Schuckit et al., 1998, 1999, 2003). In addition, diagnostic models that placed a 
greater emphasis on physiological reactions to drug use have exhibited greater reliability and 
validity compared to DSM diagnostic models. Such an example is the Withdrawal-Gate Model 
(Langenbucher et al., 2000), which held that drug withdrawal is a gate criterion – a criteria 
necessary to meet o be categorized as dependence. This model has demonstrated significantly 
greater reliability, concurrent, and predictive validity when separating participants as either 
having a substance dependence or substance abuse disorder compared to the DSM-IV 
(Langenbucher et al., 2000). Finally, the physiological/-psychological dependence distinction 
may have incremental value to testing a theoretical model explaining the development and 
maintenance of addiction from a neurocognitive perspective: The Impaired-Response Inhibition 
and Salience Attribution model of addiction (i-RISA; Goldstein & Volkow, 2002, 2011).  
The i-RISA model was constructed on the theory that an individual’s substance use can 
be conceptualized as a continuum of severity, with impulsive-voluntary drug use at the beginning 
and compulsive-habitual/uncontrollable drug use at the end (Everitt & Robbins, 2005, 2016). In 
addition, it incorporated another theory that chronic drug use dissociates “liking” from “wanting” 
the drug, in which case the reward-stimulating effects of the drugs decrease with repeated use 
while the incentive salience of the drug and drug-associated stimuli will increase (Berridge & 
Robinson, 2016; Lambert, McLeod, & Schenk, 2006; Robinson & Berridge, 1993, 2000). This 
incentive salience is the motivational value of drug-related reward, and its ability to exhibit a 




rewarding response in an organism. This is a theoretical explanation for continued substance use 
despite increasing tolerance (Calipari, Ferris, & Jones, 2014; Gardner, 2011; Kawa, Bentzley, & 
Robinson, 2016; Koob & Volkow, 2010, 2016; Siciliano, Fordahl, & Jones, 2016). 
The primary hypothesis of the i-RISA model (Goldstein & Volkow, 2002, 2011) is that 
individual with an addiction escalated from impulsive to compulsive drug use due neurological 
dysfunctions that underlie a salience misattribution, rendering drug-related stimuli to be more 
salient than non-drug stimuli. The authors theorized that the incentive sensitization of drug-
related stimuli is concomitant with an incentive desensitization of non-drug related rewards (i.e. 
food, sex and money), concomitant with growing response-inhibition impairments, leading to a 
growing inability to inhibit drug-seeking behavior in response to cues and cue-induced craving 
(Goldstein & Volkow, 2002; Koob & Volkow, 2010).  
This salience misattribution and response-inhibition dysfunction are thought to be due to 
neurological dysfunctions within the prefrontal cortex (PFC) and the anterior cingulate cortex 
(ACC) (Goldstein & Volkow, 2002, 2011; Koob & Volkow, 2010). Interestingly, the i-RISA 
model holds that this dysfunction was due to chronic substance use and factors related to 
physiological dependence, particularly drug withdrawal. The authors hypothesized that 
neuroplastic changes following these opposing hedonic mechanisms (drug reward vs drug 
withdrawal) lead to the manifestation of saliency and stimulus processing biases towards drugs 
relative to non-drug rewards and response-inhibition dysfunctions by altering the functionality of 
these cortical systems. This was an extension of an older model holding that addiction manifests 
by repeatedly cycling through three stages: binge/intoxication, withdrawal/negative affect, and 
craving/preoccupation (Koob & LeMoal, 1997, 2005, 2008a, 2008b).  




According to this three-stage model of addiction, neuroplastic changes occurred by 
cycling through these three stages repeatedly, which would have sensitized the incentive salience 
of drug-related stimuli. These changes are thought to be due to activity within the reward-system 
(i.e. ventral striatum, ventral tegmental area) in response to drug administration, and antireward-
system activity during drug-withdrawal (Koob, 2017; Koob & Le Moal, 2005; Koob & Volkow, 
2010, 2016). This antireward-system, consisting primarily of anxiety and stress related regions 
(i.e. amygdala, bed nucleus of the stria terminalis), would have acted as an allostatic mechanism 
to return the brain to a hedonic and physiological baseline (Gardner, 2011; Koob, 2009, 2010, 
2013, 2017; Koob & Le Moal, 2008a, 2008b). The i-RISA model holds that the neuroplastic 
changes leading to drug-reward incentive sensitization would be concomitant with non-drug-
reward incentive desensitization. 
While untested, one might suspect that individuals with a physiological dependence to a 
substance, characterized by drug-related behavioral dysfunctions, chronic substance use, 
tolerance and periods of withdrawal following use-cessation, would exhibit the most severe i-
RISA deficits, consistent with the three-stage model of addiction and the i-RISA model itself. 
The current thesis will test this hypothesis as a means of empirically testing the accuracy of this 
widely accepted model of addiction, as well as the implication of physiological and 
psychological dependence dichotomization on understanding and assessing addiction.  
Defining psychopathy 
Psychopathic personality disorder, more commonly referred to as psychopathy, is a 
personality disorder characterized by interpersonal, affective, lifestyle and antisocial features 
(Hare, 2003). Psychopathic individuals are characterized by callous-unemotional traits, such as 
manipulativeness, lack of remorse and empathy, a shallow range of emotions, a self-destructive 




lifestyle, impulsivity, irresponsibility, resistance to stress, a superficial charm and narcissistic 
view of himself and a strong inclination to commit antisocial behaviour (Hare, 2003; Cleckley, 
1955).  
While there has been some disagreement with regard to the specific diagnostic criteria for 
the disorder, particularly in terms of whether psychopathy is characterized as a combination of 
two factors (Hare, 2003), three factors (Cooke & Michie, 2001), or four factors (Hare, 2003), the 
“gold-standard instrument” used to diagnose psychopathy is the Hare Psychopathy Checklist-
Revised (PCL-R; Hare, 2003; Lynam & Gudonis, 2005). The PCL-R conforms to a two factor 
model, which separates psychopathy into a) interpersonal and affective traits (which attempts to 
characterize a “selfish, callous and remorseless use of others” [Hare, 2003, p.79]); and b) 
lifestyle and antisocial traits (which attempts to characterized a “chronically unstable, antisocial 
and socially deviant lifestyle” [Hare, 2003, p.79]). A summary of this model, and the breakdown 
of each factor, can be found in Table 2. It should be noted that factor analyses have yielded two 
items, “promiscuous sexual behaviour” and “many short-term marital relationships” that do not 
adhere to a particular factor. 
Results on the comorbidity between psychopathy and addiction 
Many studies have noted a comorbidity between SUDs and psychopathic traits (see Table 
3 for a list of research studies which have focused on the psychopathy-SUD comorbidity). For 
instance, Stålenheim and von Knorring (1996) demonstrated that roughly 93% of participants 
with psychopathy had a substance use disorder. Moreover, participants noted as psychopaths 
were more likely to engage in polysubstance use, and have a diagnosis of alcohol, amphetamine, 
barbiturate, and opioid use disorder (Smith & Newman, 1990), and psychopathic traits exhibited 
positive correlations with symptoms of alcohol, cannabis, opioid, and cocaine use disorders 




(Walsh, Allen, & Kosson, 2007). Finally, a meta-analysis demonstrated positive correlations 
between psychopathic traits and non-alcohol SUDs, however no significant correlation was 
observed between psychopathic traits and alcohol use disorder (Hemphil, Hart, & Hare, 1994).  
Table 2 
Factor structure of the Hare Psychopathy Checklist-Revised 
Trait Factor 1 Factor 2 Other 
1. Glibness/superficial charm X   
2. Grandiose sense of self-worth X   
3. Pathological Lying X   
4. Conning/manipulativeness X   
5. Lack of remorse/guilt X   
6. Shallow affect X   
7. Callousness/Lack of empathy X   
8. Failure to accept responsibility for own actions X   
9. Need for stimulation/proneness to boredom  X  
10. Parasitic lifestyle  X  
11. Early behavioral problems  X  
12. Poor behavioral problems  X  
13. Lack of realistic, long-term goals  X  
14. Impulsivity  X  
15. Irresponsibility  X  
16. Juvenile delinquency  X  
17. Revocation of conditional release  X  
18. Criminal versatility  X  
19. Promiscuous sexual behavior   X 
20. Many short-term marital relationships   X 
Note. Adapted from Hare (2003). 
While this body of research generalized SUDs as a category of psychopathologies that 
includes substance use, abuse, and dependence disorders, studies have assessed specific 
relationships between psychopathic traits and substance use severity, substance abuse, and 
substance dependence. Coid, Yang, Ullrich, Roberts, and Hare (2009) demonstrated that 
participants who had used cannabis within the last year and had ever used heroin, cocaine, and/or 
amphetamines, and were diagnosed with a substance dependence disorder, had a greater number 
of psychopathic traits. Psychopathic traits also correlated with the number of years regularly 
using addictive substances among adult participants (excluding alcohol; Cope et al., 2012, 




2014a) and youth subjects (Hillege, Das, de Ruiter, 2010). Individuals with a high level of 
psychopathic traits are also more likely to receive a diagnosis of substance abuse or substance 
dependence (Cauffman, Kimonis, Dmitrieva, & Monahan, 2009; Jones & Miller, 2012). Finally, 
the severity of dependence on opioids, hallucinogens, and stimulants positively correlated with 
psychopathic traits (Hopley & Brunelle, 2012).  
More recently, neuroimaging work has aimed to better understand the underlying nature 
of the relationship between psychopathic traits and SUDs. While the early evidence remains 
nascent, and has elicited somewhat inconsistent findings, several patterns begin to emerge. While 
certain neuroimaging studies coincide with empirical studies of the comorbidity between 
psychopathy and SUDs (i.e. Buckholtz et al., 2010), others (i.e. Cope et al., 2014a) coincide 
more with clinical case reports suggesting a disconnection, and moreover, a resilience in 
psychopathic individuals to substance dependence (Cleckley, 1941). Such inconsistencies 
between neuroscience and psychometric research on the comorbidity between psychopathy and 
SUDs raise question about the implication of psychopathy on the development of neurocognitive 
abnormalities promoting addiction; in particular: neural processing of drug- and non-drug-
rewards. I present a body of research assessing the relationship between psychopathic traits and 
neural processing of drug and non-drug rewards within participants with varying levels of 
substance dependence, as a means to reconcile the psychopathy-addiction inconsistency and 
further our understanding of the development of substance dependence and the implication of 









Summary table of the comorbidity between psychopathy and SUDs 
 Psychopathy is associated with…  




Blackburn & Coid, 1998 X    
Cauffman et al., 2009   X X 
Coid et al., 2009  X   
Colins, Andershed, & 
 Pardini, 2015 
 X   
Cope et al., 2012  X   
Cope et al., 2014a  X   
Hart, Forth, & Hare, 1991    X 
Hawes et al., 2015* X X   
Hemphil et al., 1994* X    
Hillege et al., 2010  X   
Hopley & Brunelle, 2012    X 
Jones & Miller, 2012   X  
Kennealy et al., 2007 X X   
Mailloux, Forth, & 
Kroner, 1997 
  X  
Reardon, Lang, & Patrick, 
 2002 
X    
Stålenheim & von 
Knorring, 1996 
X    
Smith & Newman, 1990 X    
Sylvers, Landfield, & 
Lilienfeld, 2011 
  X  
Walsh et al., 2007 X   X 
* Meta-analysis. 
Drug-cue neural activity in addiction: Relationship to psychopathy 
One neurocognitive feature of addiction that may yield important implications for 
understanding the comorbidity between psychopathy and addiction is drug-cue reactivity. 
Individuals with SUDs exhibit greater physiological, cognitive, and behavioral reactivity (Carter  
& Tiffany, 1999; Cooney et al., 1997; Drobes, 2002), as well as an increased craving for the drug 
in response to these cues (Kuhn & Galinat, 2011; Koob & Volkow, 2010). Drug-cue reactivity 
has also been assessed using neuroimaging methods, including functional magnetic resonance 
imaging (fMRI) and positron-emission tomography (PET). Meta-analyses of the neural response 




to drug-cues have demonstrated that individuals with SUDs exhibit significantly greater drug-cue 
reactivity within the ventral striatum, amygdala, orbitofrontal cortex (OFC), posterior cingulate 
cortex, ACC, putamen, caudate, insula, dorsolateral and dorsomedial prefrontal cortex 
(DMPFC), and cuneus/precuneus (Chase, Eickoff, Laird, & Hogarth, 2011; Engelmann et al., 
2012; Schacht, Anton, & Myrick, 2013; Yalachkov, Kaiser, & Naumer, 2012). Studies have 
assessed cue-reactivity within individuals with alcohol, nicotine, and cocaine use disorders. 
Recently, Kuhn & Gallinat (2011) conducted a meta-analysis of common drug-related neural 
activation patterns between nicotine, alcohol, and cocaine-cue reactivity, and demonstrated that 
only the ventral striatum exhibited significant concurrence of activation to cocaine-, alcohol-, 
and nicotine-cues.  
 This increased neural reactivity towards drug-related rewards may have come at the 
expense of non-drug rewards. For example, Garavan et al. (2000) demonstrated that cocaine 
users exhibited significantly greater reactivity within the PFC and ACC in response to cocaine-
related stimuli relative to sex-related stimuli. Goldstein et al. (2009) demonstrated greater 
reactivity among individuals with a cocaine use disorder within the ACC in response to cocaine-
related stimuli relative to monetary rewards. Finally, George et al. (2001) demonstrated greater 
neural reactivity within the PFC among individuals with an alcohol use disorder in response to 
alcohol-related pictures relative to pictures of non-alcohol beverages. This drug-cue reactivity 
may have implications in determining one’s prognosis of this disorder, as drug-cue reactivity 
being associated with an increased propensity to relapse once abstinent, and shorter abstinence 
periods (Claus & Shane, 2018; Courtney, Schacht, Hutchison, Roche, & Ray, 2016; Janes et al., 
2010).  




Surprisingly, the relationship between psychopathic traits and drug-related stimulus-
processing contrasted psychopathy-comorbidity research. Cope et al. (2014) assessed the 
relationship between psychopathic traits (measured with the PCL-R) and drug-cue reactivity 
among offenders with a substance dependence disorder. The authors demonstrated a negative 
correlation between psychopathic traits and neural reactivity to drug-related stimuli within 
several regions noted to have an increased sensitivity to drug-related stimuli in individuals with 
SUDs, including the DMPFC, precuneus, ACC, ventral striatum, caudate, and putamen (Cope et 
al., 2014). Another study among young offenders also demonstrated a negative correlation 
between psychopathic traits and drug-cue reactivity within the ACC, ventral striatum, caudate, 
putamen, amygdala, hippocampus, and insula (Vincent et al., 2017). This countered what we 
would have expected considering studies have demonstrated that psychopathic traits exhibited 
positive correlations to substance use (i.e. Coid et al., 2009) and antisocial and lifestyle 
psychopathic traits were positively associated with ventral striatal dopaminergic response to 
drug-related stimuli (Buckholtz et al., 2010), a theoretically central component to neural 
reactivity increases to drug-related stimuli and neural processing biases to drug-related rewards 
in addiction (Goldstein & Volkow, 2002; Koob & Le Moal, 1997; Koob & Volkow, 2010; 
Robinson & Berridge, 1993, 2000). Therefore, this raises questions about the nature of the 
comorbidity between psychopathic traits and SUDs. 
 However, there are limitations of both Cope et al. (2014) and Vincent et al. (2017) that 
must be addressed prior to making conclusions on the relationship between psychopathic traits 
and drug-stimulus processing. The first is the use of neutral stimuli as a control condition. Such a 
control condition may not have served as a control condition capable of arousing the brain’s 
reward-processing and motivational neural systems in drug-independent individuals as drug-




related stimuli arouses such systems in individuals with SUDs (Versace et al., 2017). Non-drug 
rewards, such as food, may serve as a more appropriate control condition, as they would allow to 
assess the extent to which drug-related rewards are held to a higher accord than non-drug reward 
in addiction. In non-dependent healthy individuals, food has been found to activate reward-
processing neural regions that overlap with regions exhibited drug-related reactivity substance-
dependent individuals (Noori et al., 2016; Tang et al., 2012; Tomasi et al., 2011). Therefore, we 
know that individuals without a substantial history of substance use exhibited increased neural 
reactivity in response to food rewards that is similar to the neural response to drug-related stimuli 
in individuals with SUDs. This approach is also more in line with the i-RISA model (Goldstein 
& Volkow, 2002), which holds that the incentive sensitization of drug-related stimuli comes at 
the expense of the incentive salience of other non-drug rewards, and that this may lead to a 
neural processing bias in reward- and motivational regions towards drug-related stimuli 
compared to biologically-necessary rewards (i.e. food).   
  By examining the relationship between psychopathic traits and drug-related neural 
processing relative to a non-drug reward, we could determine whether the decreased neural 
reactivity in highly psychopathic individuals was specific to drug-related rewards or would 
generalize to all reward. In the studies presented in this thesis, we assessed the relationship 
between psychopathic traits and drug- and food-related neural processing, testing two 
possibilities. The first possibility was that while drug-related neural reactivity was decreased in 
highly psychopathic individuals, non-drug reward neural reactivity would be further decreased to 
compensate for this abnormality, rendering these individuals more likely to use the substance, 
and explaining the comorbidity between psychopathic personality disorder. Structural 
abnormalities related to psychopathy within several corticolimbic regions, including the 




DMPFC, OFC, ACC, insula, striatum, and the amygdala (Boccardi et al., Cope et al., 2014b; de 
Oliveria-Souza et al., 2010; Ermer et al., 2012, 2013; Glenn et al., 2010; Hyde et al., 2014; 
Pardini et al., 2014; Yang et al., 2009, 2010), may have caused a different decalibration of this 
corticolimbic network with chronic substance use that rendered non-drug reward further 
decreased in value compared to drug-related rewards, which were devalued themselves.  
 This first possibility was assessed by examining the individual and shared effect of 
psychopathic traits and substance use severity on drug- and food-stimulus processing in the 
brain. This would have demonstrated not only how substance use severity and psychopathic 
individual affect drug- and food-stimulus processing, but also whether and how psychopathic 
traits modulate the effect of substance-use severity on the magnitude of the difference in neural 
reactivity between drug-related neural reactivity and food-related neural reactivity. If the first 
possibility is correct, psychopathic traits should increase a drug > food neural processing bias 
and modulate the effect of substance use severity in which high levels of psychopathic traits 
would increase drug > food processing in participants with low and high levels of substance use.  
 However, the second possibility was that psychopathic traits would fail to show this 
neural processing bias towards drug-related rewards rather than non-drug rewards. As 
psychopathic traits positively correlated with substance use (i.e. Coid et al., 2009) and were 
associated with sensitized dopaminergic response to substances (Buckholtz et al., 2010), it is 
possible that psychopaths did experience the strong positive reinforcement properties of drug 
use. However, psychopathic traits may have also facilitated a resilience to the development of 
these neural processing biases, possibly due to abnormalities in the experience of physiological 
factors that promotes the development of this bias. The i-RISA model holds that the experience 
of physiological factors of dependence, such as withdrawal and tolerance, would facilitate the 




development of such biases towards drug-related rewards (Goldstein & Volkow, 2002, 2011). 
Consistent with this theory, neuroimaging studies have demonstrated that withdrawal sensitizes 
drug-cue reactivity in individuals with SUDs within the striatum, ACC, DMPFC, hippocampus, 
and posterior cingulate cortex (Jasinska, Stein, Kaiser, Naumer, & Yalachkov, 2014; Lou, Wang, 
Shen, & Wang, 2012; McClernon, Hiott, Huettel, & Rose, 2005; McClernon, Kozink, Lutz, & 
Rose, 2009). While no study has assessed the specific relationship between psychopathy and 
either psychological/-physiological dependence, nor between psychopathic traits and specific 
SUD symptomology, clinical case examinations offer evidence that psychopathic individuals 
may be resilient to withdrawal (Cleckley, 1955), and therefore, potential neural changes. This 
may have rendered highly psychopathic individuals unable develop this incentive sensitization of 
drug-related rewards and incentive desensitization of non-drug rewards, leading to the results 
from Cope et al. (2014) and Vincent et al. (2017). As a result, highly psychopathic individuals 
may be at risk for high rates of substance use and may in fact develop a psychological 
dependence to the drug of choice, however they may be resilient to the development of a 
physiological dependence and associated neurocognitive dysfunctions. This second possibility 
was assessed by examining the relationship between psychopathic traits and the two forms of 
dependence (psychological/- physiological dependence), followed by an examination of how the 
relationship between psychopathic traits and drug- and food-stimuli neural processing changed 
based on the variant of dependence.  
The current thesis: Overview of studies 
 This body of work looked to further our understanding the nature of the comorbidity 
between psychopathic traits and addiction by assessing the relationship between psychopathic 
traits and neural reactivity to drug- and food-related stimuli, and whether psychopathic traits 




modulates the effect of substance use severity on this neural reactivity. This relationship was first 
assessed in cocaine-dependent and cocaine-independent individuals and was followed by 
subsequent analyses that separated cocaine dependence into two variants: psychological and 
physiological dependence. The following gives a brief overview of each study and the attempt 
made to understand the psychopathy-addiction comorbidity using a sample of probation/parolees 
from the Albuquerque, New Mexico area.    
Study 1 
 First, we assessed the relationship between psychopathy and substance dependence, as 
well as the relationship between psychopathic traits and drug- compared to food-stimulus 
processing in the brain using an fMRI cue-reactivity task. We additionally assessed how 
psychopathic traits interacted with substance use severity to affect any neural processing 
abnormalities seen in dependent individuals. This study will assess whether psychopathic traits 
plays a role in components of the i-RISA model, in particular the neural-processing bias for 
drug-related rewards relative to non-drug rewards. The results of this study have already been 
submitted for publication into the academic journal Frontiers in Human Neurosciences.   
Study 2 
 We then assessed how this neural reactivity to drug- and food-related neural reactivity is 
modulated by whether the participant had a physiological or psychological dependence. This 
analysis would determine whether theories on physiological dependence being a more severe 
form of an addictive disorder could be true based on the magnitude of the neural reactivity bias 
hypothesized by the i-RISA model. We then assessed the relationship between substance use and 
psychopathic traits with the variant of dependence and assessed how the variant of dependence 




modulated the effect of psychopathic traits, substance use severity, and their interaction on this 
drug > food neural reactivity.  
 In particular, I was interested in evaluating the four following questions: 1) whether the 
hypothesized processing bias outlined in contemporary theories of addiction could be observed 
in human subjects with a SUDs in an fMRI study; 2) whether physiological SUD patterns (i.e. 
withdrawal and tolerance) have a significant effect on neural processing biases; 3) whether 
psychopathic traits are truly associated with a desensitized neural response to drug-cues, or 
exhibit a similar or even sensitized processing bias observed in substance-dependent individuals; 
4) whether psychopathic traits interact with the effects of substance use, tolerance and 





















Psychopathic individuals have frequently been characterized as impulsive and 
irresponsible risk takers, with an altered sensitivity to reward and reward-related stimuli 
(Beszterczey et al., 2013; Cleckley, 1955; Dean et al., 2013; Hare, 2003; Hopley & Brunelle, 
2012; Mitchell et al., 2002; Morgan et al., 2011; Ross et al., 2007; Salim, van der Veen, van 
Dongen, Franken, 2015; Wallace, Malterer, & Newman, 2009). Given that these are also 
characteristics that predict initial and prolonged drug use (Koob & Volkow, 2010; Leeman et al., 
2014; Woicik et al., 2009), it may come as no surprise that psychopathy has been associated with 
heightened levels of substance use (Coid et al., 2009; Cope et al., 2012, 2014; Hawes et al., 
2015; Hillege et al., 2010; Kennealy et al., 2007), as well as increased diagnosis of both 
substance abuse (Cauffman et al., 2009; Colins et al., 2015; Jones & Miller, 2012; Mailloux et 
al., 1997; Sylvers et al., 2011) and substance dependence (Hart et al., 1991; Hopley & Brunelle, 
2012; Walsh, et al. 2007).   
Beyond this behavioral and diagnostic overlap are additional commonalities. For 
instance, both disorders appear characterized by dysfunction within common corticolimbic 
regions underlying reward-related processing (psychopathy: Blair, 2015; substance use disorders: 
Koob & Le Moal, 2001). Within adults with psychopathic traits, this dysfunction appears to 
manifest as consistently heightened sensitivity to a wide variety of rewarding stimuli within the 
ventral striatum, including monetary (Bjork et al., 2012; Buckholtz et al., 2010; Carré et al., 
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2013; Pujara et al., 2013) and drug-related (Buckholtz et al., 2010) rewards (though we note that 
children/adolescent with heightened callous-unemotional traits often show a normal [Byrd et al., 
2018; Murray et al., 2017] or hyposensitive [Veroude et al., 2016] ventral striatal response to 
reward). Psychopathic traits have also been associated with increased functional connectivity 
between the ventral striatum and the dorsomedial prefrontal cortex (DMPFC) in response to 
monetary rewards (Geurts et al., 2016).  
A considerably larger body of work indicates that individuals with substance use 
disorders also exhibit a heightened reward sensitivity throughout the corticolimbic system 
(Stewart et al., 2013). However, whereas psychopathic traits appear predictive of broadly 
increased sensitivity that spans multiple reward categories, individuals with prolonged drug use 
histories show a sensitivity-profile wherein reward-sensitivity shifts in favor of the individuals’ 
drug of abuse, particularly within the DMPFC, ACC, striatum, amygdala, and insula (Chase et 
al., 2011; Engelmann et al., 2012; Garavan et al., 2000; Kilts et al., 2001; Kühn & Gallinat, 
2011; Ray et al., 2015; Tomasi et al., 2016), at the expense of non-drug rewards (e.g., sex-related 
[Garavan et al., 2000], monetary [Goldstein et al., 2009]). This substance-induced decalibration 
of the reward system has been theorized as central to the development and maintenance of 
craving, drug-seeking, and compulsive drug use, wherein the individual is motivated to seek out 
the strong reward properties of the drug, and has difficulty obtaining that level of reward through 
non-drug rewards (Goldstein & Volkow, 2002, 2011; see also Koob & Le Moal, 1997, 2008a; 
Koob & Volkow, 2010). 
How these reward-dysfunctions are related and whether they explain the comorbidity 
between the two disorders remains poorly understood. It is possible that heightened psychopathic 
traits predisposes to a sensitized reward-response to drugs, which would be related to a reward-




processing bias towards drug-related rewards compared to non-drug rewards. While little work 
has yet been directed towards such issues, one recent study provides preliminary support. In this 
study, drug-naïve individuals had their neural reactivity evaluated during a controlled 
amphetamine administration (Buckholtz et al., 2010). Results indicated that impulsive/antisocial 
psychopathic traits were associated with an increasingly sensitized ventral striatal dopaminergic 
response to the amphetamine administration. Such a heightened corticolimbic dopamine 
response to drugs is believed to serve as a catalyst for the development of longer-term 
neuroplastic changes to drug-related incentive salience, and a resultant processing bias for drug-
compared to non-drug-rewards (Goldstein & Volkow, 2002; Koob & Le Moal, 1997; Koob & 
Volkow, 2010; Robinson & Berridge, 1993, 2000). Thus, the inclination for individuals with 
heightened psychopathic traits to select highly risky rewards (Mitchell et al., 2002), combined 
with their initially-heightened reward sensitivity (e.g., Bjork et al., 2012), may increase the 
likelihood of corticolimbic sensitization to drug-related rewards (followed by a substance 
induced desensitization to non-drug rewards). As a result, they would continue to abuse these 
drugs and may be more likely to develop substance dependence disorders. 
 Recently, a small amount of work has begun to investigate this hypothesis by assessing 
drug-stimulus processing in substance users with varying levels of psychopathy. Cope et al. 
(2014) assessed the relationship between psychopathy and the neural response to drug-related 
and neutral stimuli among 137 male offenders meeting the DSM-IV-TR (American Psychiatric 
Association, 2000) criteria for lifetime dependence to heroin, cocaine or methamphetamines. 
Results identified a negative correlation between psychopathic traits and neural response to drug 
versus neutral images in the ACC, putamen, caudate, amygdala, and ventral striatum. Vincent et 
al. (2017) largely replicated these results utilizing the same stimulus-presentation task in 54 male 




adolescent offenders (44 of which had a stimulant use disorder) who manifested a negative 
correlation between psychopathic traits and neural response to drug versus neutral images in the 
ACC, amygdala, caudate, hippocampus, insula, and striatum.   
While these results seemingly counter our hypothesis, several features of Cope et al. 
(2014) and Vincent et al. (2017) suggest that additional investigation may be in order. First, both 
studies used on a non-reward control condition. While this provides a true non-reward baseline, 
it precludes the ability to determine whether the psychopathy-related reduction in cue-elicited 
reactivity was specific to drug-related stimuli or could instead be due to a more general reduction 
in reactivity to all reward-related stimuli (see Versace et al., 2017 for commentary on the pitfalls 
of neutral conditions). This distinction may be particularly important given that substance use 
disorders are known to preferentially bias neural systems towards drug-related stimuli and away 
from other categories of non-drug rewards (i.e. food; Baler & Volkow, 2006; Rubinstein et al., 
2011; Schwienteck & Banks, 2015; Schwienteck et al., 2015; Versace et al., 2017; Volkow et al., 
2016; Volkow et al., 2010). To this end, the present study made use of a carefully matched non-
drug reward (i.e., food) condition as our control condition. By including a food-reward condition, 
the paradigm afforded careful isolation of drug reward-related neural activity from natural 
reward-related activity. Thus, we could assess whether psychopathic traits are related to an 
abnormal neural sensitivity to all types of reward, or whether this abnormality is specific to drug-
related rewards.   
 A second potential limitation of Cope et al. (2014) and Vincent et al. (2017) is that they 
did not include a non-dependent control condition. While we would not necessarily expect 
psychopathy to mediate neural responses to drug cues in a non-dependent group, the inclusion of 
this group can confirm the specificity of any mediated response in individuals with a previous 




drug-use history. Such specificity may provide additional clues towards the etiological basis of 
any observed psychopathy-related influences. To this end, we recruited both dependent and non-
dependent subjects into the present study.  
We hypothesized drug- and food-related hemodynamic signal-change differences in the 
insula, DMPFC, ACC, amygdala, and the striatum between dependent and non-dependent 
groups. We additionally hypothesized that psychopathic traits would mediate neural reactivity to 
drug versus food stimuli in the dependent group. Finally, we predicted that psychopathic traits 
would interact with substance use, such that the influence of psychopathic traits on drug and food 
processing would be modulated by the level of substance use.  
Methods 
Participants 
 Our sample consisted of 105 adult probation/parolees (70 males) residing in the great 
Albuquerque, New Mexico area. Participants were recruited through probation/parole offices, 
halfway houses, and drug treatment centers, as well as through targeted advertisements in local 
print and online classifieds. Classified ads specifically targeted probation/parolees who did and 
did not meet DSM-IV-TR diagnostic criteria for lifetime cocaine dependence. Exclusion criteria 
included loss of consciousness for longer than 30 minutes, lifetime history of psychotic disorder, 
diagnosis of major depressive disorder within last 6 months, and standard MR-related exclusion 
criteria including metallic implants, permanent retainer or braces, irremovable piercings, other 
metal irremovable metallic objects, and pregnancy. Diagnosis of anxiety disorders, including 
obsessive-compulsive disorder, were documented but not used as exclusion criterion. This study 
was approved by the Institutional Review Board of the University of New Mexico and the 
Research Ethics Board of the University of Ontario Institute of Technology and carried out in 




accordance with their recommendations. All subjects gave written informed consent in 
accordance with the Declaration of Helsinki. 
Clinical/forensic measures  
 Cocaine dependence. Lifetime history of cocaine dependence was diagnosed via the 
Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I/P; First et al., 2002). 
Psychiatric symptoms of all disorders are coded 1 to 3, representing absent (1), subthreshold (2), 
or threshold/present (3). As per SCID I/P procedures, a diagnosis of cocaine dependence 
required that the participants score ‘3’ on at least three of seven diagnostic criteria. Highly 
trained graduate research personnel conducted each interview, under the guidance of a senior 
SCID trainer (R.C.; see acknowledgements). 
Psychopathic traits. The Psychopathy Checklist-Revised (PCL-R; Hare, 2003) was 
utilized to measure psychopathic traits. The PCL-R is widely considered the gold-standard 
instrument to diagnose psychopathy (Lynam & Gudonis, 2005), and has demonstrated good 
reliability and construct validity in substance abuse patients (Alterman et al., 1993; Rutherford, 
et al., 1996; Rutherford et al., 1997) and offenders (Cooke & Michie, 1997; Neves et al., 2011; 
Poythress et al., 2010; Shine & Hobson, 1997; Sullivan et al., 2006).  For the present study, PCL-
R scores were calculated based on an in-depth interview administered by highly-trained research 
personnel (trained by Dr. Shane); no subsequent file review was undertaken. It consisted of 20 
items scored 0-2, with scores ranging from 0 to 40. Both Total and Factor scores were calculated 
and evaluated with regard to primary variables of interest. Factor 1 contained eight items 
assessing interpersonal and affective deficits; Factor 2 contained 10 items assessing lifestyle and 
antisocial deficits.  




 Drug use. In addition to SCID-I/P diagnoses substance dependence disorders, a trained 
examiner also administered a modified version of the Addiction Severity Index-Expanded (ASI-
X; McLellan et al., 1992) to assess the frequency and duration of participants’ regular substance 
use history. Following data collection, three composite drug use scores were calculated by 
summing the total number of years of use of drugs that fell into one of three categories: Major 
Drugs (e.g., Cocaine, heroin, methamphetamines), Minor Drugs (e.g., Cannabis, nicotine, 
hallucinogens), and Alcohol (see Claus & Shane, 2018). For example, if a participant used 
cocaine for five years, methamphetamines for five years, and heroin for three years, the effective 
rate of Major Drug use was calculated as 13 years.   
Cue-elicited craving task 
 Participants performed two identical runs of a cue-elicited block-design craving task 
randomly sequenced and presented via E-Prime 2.0 (Psychology Software Tools, Pittsburgh, 
PA). Within each run, participants were presented with 14 videos ranging from ~10,000-
14,000ms in duration. Videos were organized into two categories: video depicting people 
preparing or using cocaine/crack (DRUG); or videos depicting people preparing/eating various 
foods (FOOD). The distinction between use and preparation of drugs and food was made for 
purposes outside the scope of this study — thus they were collapsed for all analyses within the 
current study. Participants were simply asked to watch the videos and were not required to make 
any formal assessments during video playback. However, following each video, participants 
were prompted to rate their level of craving on a scale from 1 (lowest) to 4 (highest) on a four-
button keypad. Following a jittered inter-trial interval (2500ms, 3500ms, 5000ms) to aid 
deconvolution from the standard hemodynamic response function (HRF), the next video was 
presented. 




Image acquisition parameters and preprocessing 
 Participants were scanned using a Siemens 3T TrioTim MRI scanner with advanced SQ 
gradients (max slew rate 200 T/m/s) at the Mind Research Network imaging center. Whole-brain 
T2*-weighted images were acquired from a 16-element phased-array head coil and an iPAT 
echo-planar imaging (EPI) gradient-echo pulse sequence (TR=2000ms; TE=29ms). Image 
acquisition utilized a 75º flip angle and created a 24 x 24 cm FOV on a 64 x 64 matrix, 
generating 33 slices of 3.5mm covering the entire brain (roughly 150mm) and creating a 3.4 x 
3.4 mm in-plane resolution. Head motion was limited using padding and restraints. 
 Brain images were preprocessed using a custom pipeline with Statistical Parametric 
Mapping 5 (SPM5; http://www.fil.ion.ucl.ac.uk/spm). Motion parameters were collected along 
six dimensions (x, y, z; pitch, yaw, roll) and corrected using INRIAlign (Freire & Mangin, 
2001), which applies an algorithm with a non-quadratic function, unbiased by local signal 
changes, that reduces the influence of intensity differences between slice images. No participants 
demonstrated head movement exceeding 5mm. Images were then normalized according to the 
standard single-subject MNI template and smoothed with a 10mm Full Width Half-Maximum 
(FWHM) Gaussian smoothing kernel.  
Data analytic strategies 
 Psychometric data and correlations with psychometric data were analyzed within the 
Statistical Package for the Social Sciences 24 (SPSS 24; Industrial Business Machines [IBM], 
2016).  
First-level neuroimaging analyses were performed using a custom SPM5 analysis script 
to extract blood-oxygen-level-dependent (BOLD) signals throughout the task. The first-level 
design matrix included video presentation as one event separated into four conditions (depicting 




drug preparation, drug use, food preparation, and food use). Mean functional images of blood 
oxygen-level-dependent signals throughout the whole brain were extracted from each of the four 
conditions. This model also included six movement parameters (x, y, z, yaw, pitch, roll) that 
were covaried out of the model as variables of no interest. T-contrasts were then computed at the 
first level to assess changes in hemodynamic response during the duration of the DRUG and 
FOOD videos relative to baseline and to each other.  
 Second-level neuroimaging analyses were conducted using a mixed-model flexible-
factorial ANOVA in SPM12. Subject and Video Type (DRUG, FOOD) were included as within-
group factors, and Group (Dependent, Non-Dependent) was included as a between-group factor. 
Higher-order main effects of VideoType and Group, the Group*VideoType interaction, and 
targeted T-contrasts to evaluate between- and within-group differences in neural responses to 
DRUG > FOOD were interrogated within the flex-factorial model. All second level analyses 
were conducted with and without age as a null covariate; results reported below were modelled 
without age.  
Of particular interest was the extent to which PCL-R scores and/or substance use severity 
would predict the magnitude of any DRUG > FOOD processing bias identified within the 
Dependent group. To investigate this, multiple linear regression models were undertaken, with 
PCL-R Total Scores, Major Drug Use, and the PCL-R*Major Drug Use interaction term, 
included as regressors to predict BOLD response in the DRUG > FOOD contrast. These 
regressions were run separately among Dependent and Non-dependent groups, however results 
focus on the Dependent results, as these were of primary theoretical importance. Similar 
regression models were also conducted with Factor 1 and Factor 2 scores as regressors to 
evaluate the unique influence of interpersonal/affective and lifestyle/antisocial traits.  




Whole-brain results were interpreted using an uncorrected threshold of .001, combined 
with an extended cluster threshold of 132 voxels (equivalent to a p < .05 [FWE] threshold) based 
on a series of Monte-Carlo simulations run through the Alpha Simulator (AlphaSim) in the 
Resting-State fMRI Data Analysis Toolkit (REST; Song et al., 2011).  
ROI analysis 
In addition to whole-brain analyses, small-volume correction (p < .05 FWE-svc) was 
used to assess activity within six regions of interest (ROIs) : right insula (x = 40, y = -8, z = -18), 
left ACC (-6, 4, 44), left DMPFC (-5, 46, 34), right ventral striatum (11, 13, -7), left amygdala (-
32, 0, -27), and left caudate nucleus (-9, -4, 12). All central coordinates were obtained from a 
recent meta-analysis, which identified these regions within individuals with cocaine use 
disorders show specifically reactivity following presentation of cocaine-related cues (Kühn & 
Gallinat, 2011). A 6mm spherical search space was used for subcortical ROIs (i.e., ventral 
striatum, amygdala and caudate) while a 10mm sphere was used for cortical ROIs (i.e., insula, 
ACC, DMPFC).  
Parameter estimates of signal change to DRUG and FOOD videos were extracted from 
each ROI were evaluated via ANOVA and correlational models in SPSS. Both parameter 
estimates from peak-voxel coordinates and average parameter estimates from all coordinates 
within the ROI were evaluated, exhibiting identical results. Within the current study, we report 
peak-voxel coordinate analyses and results.  
Results 
Descriptive statistics and correlations between variables of interest 
Descriptive statistics of all clinical/forensic variables are displayed in Table 4; 
correlations between these variables are displayed Table 5. The mean sample age was 35.86 (SD 




= 9.04; range = 21-59), and the mean IQ was 105.47 (SD = 12.13; range = 77-140). As may be 
expected, Dependent participants reported greater lifetime drug use than Non-dependent 
participants, t=6.70, p<.001 particularly with regard to major, t=8.08, p<.001, but not minor, 
t=.224, p=.82, drug use. Moreover, Dependent participants had higher PCL-R Total, t=4.57, 
p<.001, and Factor (Factor 1, t=3.42, p=.001; Factor 2, t=4.14, p<.001) scores than Non-
dependent participants. Finally, Dependent participants also had a higher mean age, t=2.53, 
p=.013.  
Baseline sensitivity to DRUG and FOOD stimuli 
Neural responses to DRUG and FOOD stimuli were first evaluated using a 2 
(VideoType) x 2 (Group) flexible-factorial ANOVA. This analysis revealed significant main 
effects of both Group and VideoType that spanned across frontal, temporal, parietal, occipital 
and limbic cortices (see Table 6). These main effects were influenced by a significant Group x 
VideoType effect, which presented within several clusters that encompassed the left ACC, right 
insula, right ventral striatum, left amygdala, and right hippocampus.  
To evaluate the nature of this interaction effect, parameter estimates from these four ROIs 
were extracted from DRUG and FOOD trials and entered into mixed-factor ANOVA models in 
SPSS. As seen in Figure 1, Bonferroni-controlled t-tests indicated that the Dependent group 
exhibited greater DRUG-related activity  within the right ventral striatum ROI, t = 2.48, p(FWE) 
=.015; and reduced FOOD-related activity within the left ACC, t = 2.31, p(FWE) =.023, left 









Descriptive statistics and group-level differences in clinical/forensic variables 
Variable Whole sample Dependent group Non-dependent group t 
Age 35.86 (9.04) 38.28 (8.56) 33.90 (9.02) 2.53* 
IQ 105.47 (12.13) 105.47 (12.13) 105.91 (11.69) .418 
Major drug use 7.44 (8.26) 13.36 (8.40) 2.64 (3.87) 8.08*** 
Minor drug use 21.67 (16.26) 22.06 (16.38) 21.35 (16.29) .224 
Alcohol use 8.32 (9.86) 11.51 (10.50) 5.74 (8.57) 3.10** 
PCL-R Total 18.78 (7.33) 22.11 (6.83) 16.08 (6.62) 4.57*** 
Factor 1 6.40 (3.39) 7.60 (3.20) 5.43 (3.26) 3.42** 
Factor 2 11.08 (4.20) 12.83 (3.91) 9.66 (3.91) 4.14*** 
Note. t values represent test statistic of difference between Dependent and Non-dependent 
participants. Unbracketed values represent means, while bracketed values represent standard 
deviations. Factor 1 and Factor 2 scores represent scores on interpersonal/affective (Factor 1) and 
antisocial/lifestyle (Factor 2) psychopathic trait assessment on the PCL-R. 
* p <.05, **p<.01, ***p<.001 
 
Table 5 
Correlations between clinical/forensic variables among Dependent and Non-dependent 
participants 
 1 2 3 4 5 6 7 8 
Dependent group 
1. Age  -- -.31* .41** .-.27 .16 .18 .24 .13 
2. IQ     -- -.17 .09 -.12 -.10 .02 -.21 
3. Major drug use   -- -.10 .12 .33* .17 .46** 
4. Minor drug use    -- -.06 .04 .13 .02 
5. Alcohol use     -- .10 .06 .12 
6. PCL-R Total      -- .88*** .89*** 
7. Factor 1        -- .62*** 
8. Factor 2         -- 
Non-dependent group 
1. Age -- -.10 .13 -.07 .38** -.15 -.06 -.15 
2. IQ     -- -.14 .04 -.30* -.10 .05 -.20 
3. Major drug use   -- -.11 -.16 .11 -.02 .16 
4. Minor drug use     -- -.09 -.09 -.04 -.13 
5. Alcohol use      -- .21 .22 .12 
6. PCL-R total       -- .85*** .87*** 
7. Factor 1        -- .53*** 
8. Factor 2         -- 
*p <.05, **p<.01, ***p<.001 
 
 




Relative sensitivity to DRUG versus FOOD stimuli. To assess participants’ relative 
responses to DRUG versus FOOD stimuli, we conducted separate within-sample t-tests on the 
DRUG > FOOD contrast in each of the Dependent and Non-dependent groups (see Table 7). As 
hypothesized, Dependent participants exhibited significantly greater DRUG than FOOD 
reactivity within the right insula, left ACC, right ventral striatum, and left amygdala ROIs, as 
well as the left DMPFC. Greater FOOD > DRUG reactivity was only observed within the 
bilateral occipital cortex. In contrast, Non-dependent participants did not exhibit any regions 
with greater DRUG than FOOD reactivity yet demonstrated greater reactivity to FOOD than 
DRUG stimuli within the right insula, right ventral striatum, and left caudate nucleus. Between-
group differences were evaluated via a between-group t-test, which confirmed that the 
Dependent group exhibited significantly greater DRUG > FOOD activation bias than the Non-
dependent group within the right insula, left DMPFC, right ventral striatum, left amygdala, and 


























Higher-order ANOVA results 
Region Hemi. MNI (x, y, z) F Cluster size 
Main effect of Group 
Angular gyrus R 60, -54, 12 29.12* 140 
 R 57, -60, 18 20.81*  
 Middle temporal cortex R 45, -42, -6 16.32  
Middle occipital cortex R 48, -72, 27 23.23* 192 
 R 45, -78, 18 22.52*  
 Calcarine cortex  R 6, -69, 12 22.71*  
Ventral striatum R 12, 12, 0 6.89† 27 
Amygdala L -9, -6, 12 7.14† 22 
Main effect of Condition 
Middle occipital cortex L -18, -99, 3 58.24* 193 
 Fusiform gyrus L -30, -78, -18 33.95*  
Middle occipital cortex R 12, -99, 9 56.18* 268 
 Fusiform gyrus R 30, -81, -15 17.57  
Superior occipital cortex L -24, -78, 30 39.36* 244 
Superior parietal cortex R 24, -54, 60 38.22* 218 
Middle frontal cortex R 45, 18, 3 28.37* 768 
Inferior temporal cortex L -45, -45, -9 19.07 180 
ACC L -9, 6, 54 15.91† 70 
DMPFC L -3, 36, 36 9.50† 35 
Ventral striatum R 18, 12, -6 6.94† 1 
Interaction effect 
Orbitofrontal cortex  R 42, 36, -3 21.75* 342 
 Insula R 48, 15, -12 15.12  
 R 33, 21, -12 14.01  
Middle frontal cortex R 51, 15, 18 20.11* 230 
 Superior frontal cortex R 36, 15, 36 15.10  
 DMPFC R 51, 33, 18 14.71  
ACC L -6, 18, 21 19.47* 349 
 L -6, 27, 6 18.61  
Middle temporal cortex L -63, -24, -12 19.27* 159 
 L -57, -6, -6 17.83  
 Superior temporal cortex L -48, 12, -18 12.21  
Insula R 36, 0, -21 9.48† 73 
Ventral striatum R 6, 12, -6 8.48† 15 
 R 12, 18, -6 6.90†  
Amygdala L -36, 0, -24 7.87† 27 
Table represent significant activity within a mixed factors (Group * VideoType) flexible factorial 
ANOVA model. All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † 
p(svc-FWE) <.05; ACC = Anterior cingulate cortex; DMPFC = Dorsomedial prefrontal cortex; 
Hemi = Cerebral Hemisphere; MNI = X, Y, Z coordinates on a Montreal Neurological Institute 
template.  





Within- and between-group drug and food neural activity 
Region Hemi. MNI (x, y, z) t Cluster size 
Drug > Food – Dependent Group 
ACC L -9, 21, 18 6.07* 2980 
 Lateral prefrontal cortex R 45, 21, 3 5.74*  
Lateral prefrontal cortex L -42, 21, -3 5.07* 615 
 Dorsolateral prefrontal cortex L -45, 39, 15 4.95*  
 Middle frontal cortex L -57, 21, 15 4.73*  
Middle occipital cortex R 9, -99, 12 5.05* 226 
 Fusiform gyrus R 30, -81, -15 4.08  
Angular gyrus R 48, -48, 42 4.84* 150 
Postcentral gyrus L -12, -21, 57 4.27* 147 
 Precentral gyrus L -6, -9, 54 3.61  
Insula R 30, -6, -15 2.82† 44 
 R 36, 0, -15 2.69†  
ACC L -9, 9, 51 4.00† 117 
 L -9, -6, 48 2.86†  
DMPFC L 0, 39, 33 3.46† 96 
 L -3, 36, 36 3.44†  
Ventral striatum R 18, 12, -6 2.87† 14 
Amygdala L -33, -3, -24 2.35† 23 
Drug > Food – Non-dependent Group 
No significant results     
Drug > FOOD – Dependent > Non-dependent 
Ventrolateral prefrontal cortex R 42, 36, -3 4.66* 1455 
 Middle frontal cortex R 51, 15, 18 4.48*  
 ACC L -6, 18, 21 4.41*  
Middle temporal cortex L -63, -24, -12 4.39* 249 
 L -57, -6, -6 4.22*  
 Superior temporal cortex L -48, 12, -18 3.49  
Orbitofrontal cortex L -42, 24, -6 3.87 177 
 Lateral prefrontal cortex L -42, 36, 12 3.86  
 Ventrolateral prefrontal cortex L -36, 39, 0 3.32  
Insula R 36, 0, -21 3.08† 117 
DMPFC L -3, 45, 24 2.71† 89 
Ventral striatum R 6, 12, -6 2.91† 22 
 R 12, 18, -6 2.63†  
Amygdala L -39, 0, -21 2.81† 32 
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
DMPFC = Dorsomedial prefrontal cortex; ACC = Anterior cingulate cortex. Hemi = Cerebral 
Hemisphere; MNI = X, Y, Z coordinates on a Montreal Neurological Institute template. 
  





Differential sensitivity to DRUG and FOOD videos between groups 
 
Bar-charts demonstrate differences in DRUG and FOOD reactivity between the Dependent and 
Non-dependent groups. Brackets indicate significant differences at p < .05. MRIcron images 
display intensity thresholds ranging from T = 6.17 – 22.56. Coronal slices register to MNI 













Influence of PCL-R Scores and drug use severity among the Dependent group 
Given that between-group analyses confirmed that cocaine-dependent individuals were 
characterized by a DRUG > FOOD processing bias compared to non-dependent participants, we 
next, evaluated the extent to which psychopathic traits and substance use history would relate to 
this processing bias. To this end, we undertook a series of regression models in SPM12, entering 
PCL-R Total scores, years of major drug use, and the PCL-R x Major Drug Use interaction term, 
as regressors predicting DRUG > FOOD reactivity. We ran models within both Dependent and 
Non-dependent groups but focused primarily on the Dependent group given the unknown 
response to drug cues within the Non-dependent group. Dependent group results are presented in 
Table 8, and non-dependent group results are presented in Table 9. 
Results indicated that PCL-R scores, but not major drug use, were positively correlated 
with activity within several regions, including right insula and left amygdala ROIs. We followed 
up these regressions by correlating parameter estimates from these ROIs with PCL-R scores and 
observed positive correlations between PCL-R scores and DRUG-related activity in the right 
insula, r = .30 p = .043, and negatively correlated with FOOD-related activity in the right insula, 
r = -.35 p = .018, and left amygdala, r = -.33 p = .025.   
In addition, we observed a significant PCL-R x Major Drug Use interaction within the 
left DMPFC, bilateral insula, and left caudate nucleus. To decipher these interaction effects, we 
separated our Dependent group into high and low PCL-R groups (via median split; median PCL-
R = 22). The high PCL-R group exhibited greater DRUG > FOOD activity within left DMPFC, t 
= 2.62, p =.012, and right insula, t = 3.23, p =.002. We then correlated Major Drug Use 
composite scores to parameter estimates within each group separately. Parameter estimates from 
FOOD trials were subtracted from DRUG trials to obtained DRUG > FOOD reactivity estimates.  




Within the low PCL-R group, Major Drug Use correlated positively with DRUG > FOOD 
reactivity within the left DMPFC, r = .59 p = .003, right insula, r = .56 p = .005, and left caudate, 
r = .65 p = .001. In contrast, the high PCL-R group exhibited a marginally significant negative 
correlation between Major Drug Use and DRUG > FOOD within the right insula r = -.38 p = 
.071. These correlations were followed by correlations between Major Drug Use and parameter 
estimates extracted from FOOD and DRUG trials relative to baseline. Among the low PCL-R 
group, Major Drug Use correlated positively with DRUG-related left DMPFC, r = .53 p = .009, 
and left caudate, r = .48 p = .021, activity and correlated negatively with FOOD-related right 
insula, r = -.46 p = .028, and left caudate. r = -.45 p = .032, activity. The high PCL-R group did 
not exhibit any significant correlations.  
Table 8 
Multiple regression results: Total PCL-R scores, Major Drug Use, and DRUG > FOOD-related 
hemodynamic activity among the Dependent group 
Region Hemi. MNI (x, y, z) t Cluster size 
PCL-R 
Positive 
Insula R 36, -15, -15 3.46† 151 
 R 36, -12, -21 3.34†  
Amygdala 
 
L -30, -3, -24 2.95† 23 
Negative     
No significant results     
Major Drug Use 
No significant results 
PCL-R * Major Drug use 
DMPFC R 24, 30, 33 5.28* 150 
Superior frontal cortex R 15, 27, 48 3.61  
Insula R 39, -9, -9 2.78† 63 
DMPFC L -15, 42, 36 3.40† 168 
 L 3, 48, 30 2.72†  
Caudate L -3, -3, 12 3.72† 33 
 L -6, 0, 15 3.63†  
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
DMPFC = Dorsomedial prefrontal cortex. Hemi = Cerebral Hemisphere; MNI = X, Y, Z 
coordinates on a Montreal Neurological Institute template. 





Correlations between parameter estimates and Major Drug Use among Dependent participants 
with high and low PCL-R scores 
 
Scatterplots demonstrate correlations between Major Drug Use and parameter estimates of neural 
activity in response to DRUG and FOOD videos, as well as their calculated difference in activity 
(DRUG > FOOD). Solid lines indicate significant correlations at p < .05. Brain images are at a 

















Multiple regression results: Total PCL-R scores, Factor scores, Major Drug Use, and DRUG > 
FOOD-related hemodynamic activity among the Non-dependent group 
Region Hemi. MNI (x, y, z) t Cluster size 
Positive – PCL-R * Major drug use 
Caudate  L -6, 0, 6 3.94 406 
Precentral gyrus L -15, -3, 69 4.84 559 
 L -42, 0, 57 4.02  
 DMPFC L -15, 39, 45 4.61  
DMPFC R 15, 51, 21 4.81 1159 
Insula R 42, -15, -15 3.18† 132 
 R 42, 0, -21 2.99†  
DMPFC L -9, 45, 42 3.99† 171 
 L -12, 51, 30 3.86†  
 R 3, 48, 36 3.04†  
Ventral striatum R 6, 12, -6 3.44† 26 
 R 9, 9, -3 3.43†  
Positive – Factor 1*Major drug use 
DMPFC L -9, 42, 42 2.90† 132 
 L -12, 48, 33 2.71†  
Positive – Factor 2*Major drug use 
Caudate nucleus L -9, -3, 6 2.98† 33 
 L -6, -6, 9 2.88†  
 L -6, 0, 9 2.90†  
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
DMPFC = Dorsomedial prefrontal cortex. Hemi = Cerebral Hemisphere; MNI = X, Y, Z 

















Influence of PCL-R scores and drug use severity among the Non-dependent group 
The Non-dependent group, on the other hand, demonstrated no significant relationships 
between PCL-R scores, major drug use, and DRUG > FOOD reactivity. However, we noted 
significant PCL-R * Major Drug Use interaction effects in the bilateral DMPFC, right ventral 
striatum, and the left caudate (see Table S2). Analysis of parameter estimates demonstrated that 
among the High PCL-R group (PCL-R > 15), Major Drug Use positively correlated with DRUG 
> FOOD activity within the left DMPFC, r =.44, p = .012, right insula, r =.49, p = .005, and left 
caudate, r =.34, p = .058. Among the Low PCL-R group, Major Drug Use negatively correlated 
with DRUG > FOOD activity within the left DMPFC, r = -.59, p = .001, left ACC, r =-.67 p 
<.001, right ventral striatum, r =-.47, p = .014, right insula, r =-.34, p = .080, and left caudate, r 
=-.47, p = .014.  
 When correlating Major Drug Use to DRUG- and FOOD-related activity relative to 
baseline, the high PCL-R group demonstrated positive correlations between Major Drug Use and 
activity to DRUG videos within the right insula, r =.30, p = .098, and negative correlations with 
activity to FOOD videos within the left DMPFC, r =-.33, p = .071, and left caudate, r = -.43, p = 
.016. The low PCL-R group exhibited negative correlations to DRUG videos within the right 
insula, r =-.42, p = .029, left DMPFC, r =-.53, p = .005, right ventral striatum, r =-.50, p = .008, 
and left caudate, r =-.48, p = .011. In addition, they exhibit positive correlations to FOOD videos 
within the left DMPFC, r =.40, p = .037.  
Influence of psychopathy factors and drug use severity 
 Finally, to better understand how PCL-R factors differentially influenced neural 
reactivity, we undertook additional regression models with PCL-R Factor scores (and Major 
Drug Use) entered as separate regressors to predict activity in the DRUG > FOOD contrast. 




Within the Dependent group, these analyses indicated that Factor 1 was associated with activity 
in several regions, including the right insula, right ventral striatum, and left amygdala (Table 6; 
see Table S2 for results in the Non-dependent group). Analysis of parameter estimates from each 
of the FOOD and DRUG contrasts confirmed that Factor 1 scores were positively correlated with 
DRUG-related activity within right insula, r = .39 p = .006, and left amygdala, r = .30 p = .042, 
and negatively correlated with FOOD-related activity within ventral striatum, r = -.31 p = .034, 
and left amygdala, marginal r = -.26 p = .084. Factor 2 showed no associated with DRUG > 
FOOD reactivity, and no interaction effects between Major Drug Use and Factor scores were 
identified.      
The Non-dependent group demonstrated no significant relationship between Factor 1 nor 
Factor 2 scores and DRUG > FOOD reactivity, however they did exhibit a significant Factor * 
Major Drug Use and Factor 2 * Major Drug Use interaction effects in the left DMPFC and left 
caudate, respectively. Among participants high in Factor 1 (Factor 1 > 5), Major Drug Use 
predicted an increased DRUG > FOOD reactivity within the left DMPFC, r = .46, p = .009, due 
to a positive correlation between Major Drug Use and DRUG-related activity relative to baseline, 
r = .40, p = .027. No significant correlations were observed in participants low in Factor 1 scores 
(Factor 1 < 5). Participants high in Factor 2 (Factor 2 > 10) exhibited a positive correlation 
between Major Drug Use and DRUG > FOOD reactivity within the left caudate, r = .51, p = 
.004, due to a negative correlation between Major Drug Use and FOOD reactivity, r = -.42, p = 
.022. Among participants low in Factor 2, in contrast, Major Drug Use was negatively correlated 
with DRUG > FOOD reactivity within the left caudate, r = -.51, p = .006, due to negative 
correlations to DRUG-related activity, r = -.54, p = .003.  
 
 





Multiple regression results: PCL-R Factor scores, Major Drug Use, and DRUG > FOOD-
related hemodynamic activity among the Dependent group 
Region Hemi. MNI (x, y, z) t Cluster size 
Factor 1 
Positive 
Cerebellum R 39, -63, -48 4.71 116 
 R 21, -78, -42 3.93  
Parahippocampal gyrus L -24, -21, -27 4.71 285 
 Fusiform gyrus L -27, -36, -21 4.69  
 L -39, -60, -12 3.57  
Fusiform gyrus R 27, -39, -18 4.46 200 
 R 36, -33, -18 4.18  
 Lingual gyrus R 33, -51, -3 3.52  
Insula R 39, -12, -24 4.06† 164 
Ventral striatum R 9, 9, -9 3.12† 32 
 R 9, 15, -6 3.10†  
Amygdala 
 
L -30, -3, -24 2.89† 26 
Negative 
No significant results 
    
Factor 2 
No significant results     
Use 
No significant results     
Factor 1*Major Drug Use 
No significant results 
Factor 2*Major Drug Use 
No significant results 
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
Hemi = Cerebral Hemisphere; MNI = X, Y, Z coordinates on a Montreal Neurological Institute 













We used an fMRI cue-elicited craving task to assess neural reactivity to drug-related and 
food-related stimuli within individuals with and without a cocaine dependence disorder. We first 
noted a neural processing bias for drug-related relative to food-related stimuli among cocaine-
dependent participants relative to non-dependent participants, within a variety of regions 
including the ACC, DMPFC, amygdala, ventral striatum, and insula. These results are consistent 
with a large body of neuroimaging work which has demonstrated increased corticolimbic 
responsivity to drug-related rewards compared to either neutral (Bonson et al., 2002; Chase et al., 
2011; David et al., 2005; Engelmann et al., 2012; Garavan et al., 2000; Kühn & Gallinat, 2011; 
Kilts et al., 2001; Ray et al., 2015), or non-drug rewards (Garavan et al., 2000; Goldstein et al., 
2009; George et al., 2001). Specifically, analysis of parameter estimates indicated that certain 
corticolimbic regions (i.e., right ventral striatum) exhibited increase neural sensitivity to cocaine-
related stimuli, and other corticolimbic regions (i.e., left ACC and left amygdala) exhibited 
decreased sensitivity to food-related stimuli. Together, these findings offer further support for the 
notion that individuals with substance dependence disorders exhibit a specifically heightened 
reward response for drug-related rewards, and a concomitant decrease in reactivity to non-drug 
rewards (see Goldstein & Volkow, 2002, 2011). Contemporary models of addiction (i.e., I-RISA: 
Goldstein & Volkow, 2002; antireward-theory: Koob & Le Moal, 1997; Blum et al., 2000; 
Franken, 2003) argue that destabilization of this neural sensitivity may contribute to substance-
dependent individuals’ engagement in habitual, uncontrollable drug-seeking behavior.  
Of particular interest was the extent to which either psychopathic traits or duration of 
substance use history would influence the magnitude of this neural processing bias. No main 
effect of substance use history was identified, suggesting that the addiction-related processing 




bias for drug-related stimuli may develop early in the addiction cycle (see Koob & Le Moal, 
1997), and remain stable with prolonged use. In contrast, a main effect of psychopathic traits was 
identified within the right insula and left amygdala, such that an increase in psychopathic traits 
was associated with a more severe bias Drug > Food reactivity within these regions. Analysis of 
parameter estimates indicated that the right insula, psychopathic traits were associated with 
increase in drug-related responsivity and decrease in food-related responsivity; in the left 
amygdala, decrease in food-related responsivity were found. These findings support the 
hypothesis that psychopathic traits would moderate the magnitude of drug-related reward 
sensitivity in substance abusing individuals. Considering that the insula has been noted to be 
involved in the interoceptive reward-processing of drug use (Koob & Volkow, 2016; Naqvi & 
Bechara, 2009, 2010), and the amygdala is involved in salience attribution to rewarding stimuli 
(Ding et al., 2013; Lee et al., 2013; Murray et al., 2015), psychopathic traits may impart an 
enhanced incentive sensitization to drugs and drug-related interoceptive reward, as well as an 
enhanced incentive desensitization to food-related reward.  
These results run somewhat counter to the results of Cope et al. (2014) and Vincent et al. 
(2017), which reported decreased drug-related reactivity with increasing levels of psychopathy. 
One difference worth noting is that our study focused only on cocaine dependence and utilized a 
cocaine-cue craving task, whereas Cope et al. (2014) utilized methamphetamine, heroin, and 
cocaine users, and Vincent et al. (2017) focused on stimulant users. However, we believe that a 
more important distinction between our study and these prior reports is that our study made use 
of a non-drug reward (food) control condition (rather than a neutral control condition). By using 
such a non-drug reward control condition, the present study was able to interrogate the extent to 
which psychopathy-induced variation in neural reactivity to drug-related stimuli was due to 




consistent changes in reactivity to all forms of rewarding stimuli or was instead specific to the 
processing of drug-related stimuli (see Versace et al., 2017 for discussion of problems with 
neutral control conditions). The present results appear to support the latter hypothesis: 
individuals with heightened psychopathic traits showed greater Drug > Food processing biases, 
suggestive of particularly strong desensitization of non-drug rewards. It is likely that the use of a 
neutral control condition in previous studies would have had difficulty identifying this 
distinction, and that a negative Drug > Neutral bias may preclude a positive Drug > NonDrug 
bias. For instance, psychopathic traits could associate with a decrease in drug-related reward-
processing, while also associating with a greater decrease in non-drug reward-sensitivity. Future 
research should evaluate whether the present findings, and those of Cope et al. (2014) and 
Vincent et al. (2017) can be reconciled along such lines.  
Interestingly, we also observed an interaction between psychopathic traits and substance 
use history, such that the positive correlations between substance use history and Drug > Food 
processing occurred only within participants with a low level of psychopathic traits. In contrast, 
we observed a marginally significant negative correlation within participants with a high level of 
psychopathic traits. These results suggest that the development of a specific affinity towards 
drug-related rewards in substance users may only be apparent when in combination with a low 
level of psychopathic traits. In highly psychopathic individuals, on the other hand, we observed a 
decreased sensitivity to drug-related rewards. While highly psychopathic individuals, 
characterized by a high sensitivity to rewarding stimuli (Bjork et al., 2012), initially exhibit this 
drug-specific reward sensitivity, they may begin to exhibit a premature desensitization of this 
reward-processing bias with increasing substance use. This raises further question about the 
implication of psychopathic traits on the development, maintenance of substance use disorders.  




Further study should be allocated towards the nature of the comorbidity between 
psychopathy and addiction. The fact that in the current study, and in the previous literature (Cope 
et al., 2014), we observe decreases in reward-related reactivity rather than increases, raises 
question about how reward dysfunction in psychopathic individuals moderates the development 
and maintenance of substance dependence. However, two possibilities may explain how 
psychopathic traits may be associated with decreases in drug-cue reactivity and increases in 
substance use disorders. One is that with increasing substance use, highly psychopathic 
individuals begin to lose interest in the drug, possibly due to a decrease in the novelty and 
stimulatory effect of the drug. As psychopathic individuals are characterized as novelty and 
sensation seekers (Cleckley, 1941; Haapasalo, 1990; Hare, 2003, the decrease in the novelty and 
stimulatory effect of the drug may render psychopathic individuals disinterested in the drug with 
an increasingly severe substance use history. The other explanation is a deficit in cue-processing 
within the psychopath. Psychopathic individuals have commonly been noted to exhibit deficits in 
external stimulus and cue processing, such as through gambling tasks (Mitchell et al., 2002) or 
through choice-paradigms, in which case the psychopath must decide in response to cues of both 
reward and punishment (Blair et al., 2006). As a result, presenting drug- and non-drug 
rewarding-cues in an fMRI paradigm may lack the necessary saliency for the psychopath to elicit 
strong neural activity that we hypothesize would be an explanatory factor for their high 
substance use disorder prevalence.   
Implications for treatment  
 Non-invasive neurostimulation techniques have been associated with moderate success in 
reducing drug craving sensations. Most work to date has targeted the dorsolateral PFC in 
particular (Hayashi et al., 2013; Jansen et al., 2013; Shahbabaie et al., 2014), to try to increase 




inhibitory processing. Less work has to date targeted subcortical structures directly associated 
with reward processing.  It may be that the regions identified as exhibiting abnormalities within 
our study could serve as useful targets as a means of treatment in neurostimulation protocols in 
individuals with substance use disorders. Considering our results, it is possible that such 
treatment may be successful in individuals with substance use disorders, potentially both 
psychopathic and nonpsychopathic. This corticolimbic circuit should be investigated in terms of 
its implications in treatment amenability utilizing a variety of treatment strategies.  
In addition, this study suggests that an externalizing behavior often associated with 
psychopathy could be due to neural processing biases. While it strays somewhat beyond our 
current data, it would also be interesting to consider whether neurostimulation protocols 
targeting similar regions could also benefit individuals with high levels of psychopathic traits.   
Limitations 
 One limitation with the current study is that we were unable to correlate psychometric 
craving responses with psychopathic traits or neural reactivity to food and drug stimuli due to 
lack of variance in craving responses. As a result, the relationship between psychopathic traits 
and cue-induced craving, as well as the neural underpinnings of craving, remain difficult to 
discern. In addition, as is common in forensic and addiction research, our study was only able to 
recruit a moderate sample size. Power to detect relevant effects may be particularly reduced for 
analyses that required separating our participants into those with high and low psychopathic 
traits. The modest statistical power may preclude the ability to identify smaller effect sizes. In 
addition, very few of our participants would be diagnosed officially as psychopathic, as it is 
typically required to achieve a PCL-R score of 30 to be considered psychopathic (Hare, 2003), 
and the highest PCL-R score within our sample was 34. However, there is a large body of 




research demonstrating that psychopathy is a dimensional disorder that can be conceptualized as 
a spectrum rather than through a categorical and dichotomized personality disorder (Neumann & 



























 In the first study, we demonstrated a neural processing bias towards cocaine-related 
stimuli relative to food stimuli in cocaine dependent participants within in several regions, 
including the DMPFC, ACC, ventral striatum, insula, and amygdala. We then demonstrated that 
psychopathic traits modulated this neural processing bias, sensitizing drug > food reactivity in 
cocaine-dependent individuals within the insula and the amygdala. Finally, while substance use 
did not have a main effect on drug > food reactivity, there was a significant interaction effect 
between psychopathic traits and substance use severity, in which case substance use increased 
this neural processing bias among participants with a low number of psychopathic traits, while 
slightly decreasing this neural processing bias among highly psychopathic individuals.  
 Study 1 was the first attempt at answering whether psychopathic traits were a 
predisposition or a resilience factor against neural processing biases towards drug-related 
rewards compared to non-drug rewards. From these results, we inferred that psychopathic traits 
may be a predisposition towards a neural processing bias, which might explain why psychopathic 
traits are commonly reported to be comorbid with SUDs (i.e. Coid et al., 2009; Hemphil et al., 
1994; Walsh et al., 2007). Essentially, psychopathic traits may have predisposed substance users 
to developing neurocognitive abnormalities noted to be characteristic of an addictive disorder 
according to the i-RISA model (Goldstein & Volkow, 2002). According to this theoretical model 
of addiction, chronic substance users exhibit an incentive salience misattribution, in which case a 
greater amount of salience to attributed towards drug-related rewards relative to non-drug 
rewards and facilitates further drug use and development of a dependence on this substance. It 
appears that psychopathic traits sensitized this salience misattribution, which would facilitate a 
neural processing bias we observed towards drug-related stimuli relative to food stimuli.  




 In contrast, highly psychopathic individuals began to show a desensitization of this neural 
processing bias with increasing levels of substance use. This was consistent with other studies on 
the relationship between psychopathic traits and drug-stimulus processing relative to a neutral 
control condition, in which case a negative correlation was observed between psychopathic traits 
and the neural reactivity to drug-related stimuli relative to neutral stimuli (Cope et al., 2014; 
Vincent et al., 2017). This raised the likelihood of an opposing possibility that psychopathic 
traits are a resilience factor against this drug-related neural processing bias despite high levels of 
substance use.  
 In summary, psychopathy was associated with either increases or decreases in this neural 
processing bias in substance dependent participants depending on the level of substance use 
severity, and therefore we are still unsure of the nature of the relationship between psychopathic 
traits and drug-reward and non-drug reward neural processing. However, substance dependence, 
according to DSM-IV-TR guidelines (APA, 2000), was typically sub-diagnosed into either 
psychological or physiological dependence. The primary distinction between these two forms of 
dependence is that psychological dependence consists the behavioral dysfunctions revolving 
substance use and disregard for one’s psychosocial and occupational responsibilities, and 
physiological dependence consisting of behavioral dysfunctions accompanied by symptoms of 
tolerance and withdrawal. In study 1, we grouped psychologically- and physiologically-
dependent participants into one dependent category, therefore any differences between these 
groups could not be evaluated, nor their interactions with psychopathic traits and substance use 
severity in terms of drug-stimulus processing modulation. To address this, we assessed drug- and 
food-stimulus processing using the same cue-reactivity task as Study 1 in participants 




categorized as either psychologically-dependent (Psyc-D), physiologically-dependent (Phys-D), 
or non-dependent (ND).  
While no study has compared of Phys-D and Psyc-D participants in terms of neural 
processing of drug-related stimuli, several studies have already demonstrated behavioural 
differences between these two variants of substance dependence. Subjects categorized as Phys-D 
exhibited more severe drug use patterns, endorse a larger number of health problems, were more 
likely to relapse in abstinence, and experienced a greater number of psychiatric, psychosocial 
and health-related problems in their daily lives (Lejoyeux, Claudon, McLoughlin, & Adès, 2001; 
Schuckit et al., 1998, 1999, 2003). In addition, empirical studies assessing neural reactivity to 
drug-cues have demonstrated that drug withdrawal may potentiate drug-cue neural reactivity in 
substance-dependent individuals (Jasinska et al., 2014). Such effects have been observed in 
heroin dependent (Lou et al., 2012) and nicotine-dependent participants (McClernon et al., 2005; 
McClernon et al., 2009) in several regions, including the striatum, ACC, DMPFC, hippocampus 
and posterior cingulate cortex. Finally, the i-RISA model (Goldstein & Volkow, 2002; Goldstein 
et al., 2011; Koob & Volkow, 2010), hypothesized that withdrawal played a pivotal role in the 
development of incentive salience biases towards drug-related rewards relative to non-drug 
rewards. Therefore, it is possible that physiological dependence, compared to psychological 
dependence, would be associated with a more severe neural processing bias and i-RISA 
dysfunctions.  
 The role of psychopathic traits in this dichotomization of substance dependence was also 
uninvestigated, as was the moderation effect of psychopathic traits on neural processing 
differences between Phys-D and Psyc-D participants. While no study has determined the 
relationship between psychopathy and psychological/-physiological substance dependence, 




clinical case studies have suggested that these psychopathic individuals may be resilient to 
symptoms of withdrawal (Cleckley, 1941) while no conclusion could be made about 
psychopathy and drug tolerance. Therefore, psychopathic individuals may exhibit a resilience to 
the development of a physiological dependence to a substance, particularly due to abnormalities 
in their drug use patterns and a weakened withdrawal response. This may be consistent with 
structural neuroimaging research that has demonstrated that psychopathic traits are negatively 
correlated with grey matter volume within the amygdala, particularly within the basolateral and 
central nuclei of the amygdala (Hyde et al., 2014; Yang et al., 2009, 2010). The amygdala is 
commonly reported to play a substantial role in withdrawal symptomology (Koob, 2009, 2013, 
2017; Koob & Volkow, 2010; Lee, Coehlo, McGregor, Waltermire, & Szumlinski, 2015), and 
the succeeding neuroplastic changes that render drug-related incentive salience to be increasingly 
sensitized (Koob & Volkow, 2010; Lee et al., 2013). Such structural abnormalities could render 
these individuals resilient to withdrawal, and potentially unable to exhibit a physiological 
dependence to a substance. As withdrawal is considered to play a substantial role in the 
development of deficits noted in the i-RISA model (Goldstein & Volkow, 2002, 2011), this 
raises questions about not only whether psychopathic individuals could be found 
physiologically-dependent to a substance, but also whether psychopathic traits could act in a 
compensatory manner to sensitize neural processing biases in individuals with a decreased 
likelihood of being physiologically-dependent. Essentially, the i-RISA model would need to 
consider the fact that certain individual differences, such as psychopathic traits, may compensate 
for abnormalities in the three-stage addiction cycle (Koob & Le Moal, 1997), and render the 
neural processing bias towards drug-related rewards heightened despite a lack of physiological 
dependence.  




 However, psychopathic traits were associated with decreases in drug-related neural 
reactivity (relative to a neutral control [Cope et al., 2014; Vincent et al., 2017]), and highly 
psychopathic individuals exhibited a decrease in drug-stimulus processing with increasing levels 
of use (Study 1), it is possible that psychopathic traits may be associated with decreases in drug-
stimulus processing among Phys-D participants. Such participants would have exhibited greater 
levels of substance use, as well as symptoms of withdrawal and tolerance. Based on Study 1, and 
since psychopathic traits are hypothesized to make one resilient to physiological dependence, we 
might expect that psychopathic traits would decrease this drug-related neural reactivity among 
Phys-D individuals.  
 As a means of further understanding the relationship between psychopathic traits and 
neural processing biases towards drug-related stimuli, we assessed how psychopathic traits were 
related to drug- and food-stimulus processing in the brain, primarily within the DMPFC, insula, 
ACC, caudate, ventral striatum, and amygdala within Psyc-D and Phys-D participants. 
Dependent participants were separated into their rightful categories based on their responses to 
questions relating to two criteria in the assessment of substance dependence disorder: tolerance 
and withdrawal. In addition, we assessed the influence of substance use severity on this neural 
processing bias and assessed the interaction between psychopathic traits and substance use 
severity on neural processing within each group. This essentially tests whether there is a three-
way interaction between the level of dependence, psychopathic traits, and substance use severity 
on the magnitude of this stimulus-processing bias.  
We first hypothesized that Phys-D participants would exhibit a greater neural processing 
bias towards drug-related stimuli when compared to Psyc-D and ND participants, followed by 
Psyc-D participants exhibiting a greater neural processing bias when compared to ND 




participants. In addition, we hypothesized that psychopathic traits would be associated with a 
sensitized neural processing bias towards drug-related stimuli within Psyc-D participants. In 
Phys-D participants, on the other hand, we hypothesized that psychopathic traits would be 
associated with a decreased drug-related reactivity relative to food-related reactivity. Finally, we 
expected that psychopathic traits would modulate the effect of substance use in both groups, 
however in opposite manners. We expected that our original interaction effect from Study 1 
would be observed in the Phys-D group, while the psychopathic traits would increase drug > 
food reactivity among Psyc-D participants with increasing levels of substance use. Essentially, 
Psyc-D participants would exhibit the highest levels of this neural processing bias towards drug-
related rewards relative to non-drug rewards among individuals with the highest levels of 
psychopathy and substance use severity within this group. However, with the highest levels of 
use across the sample being among Phys-D participants, psychopathic traits would decrease drug 
> food reactivity with increasing levels of use among Phys-D participants.  
Method 
Participants 
 We analyzed 101 adult probation/parolees residing in the great Albuquerque, New 
Mexico area from our previously used dataset of 105 participants in Study 1. Four participants 
were excluded from the analyses due to insufficient data from the Structured Clinical Interview 
for DSM-IV-TR Axis I Disorders (SCID-I/P; First et al., 2002), particularly in terms of the 
participant’s cocaine-dependence symptomology and whether we were able to determine non-
dependence, psychological, and physiological cocaine dependence. All inclusion and exclusion 
criteria from Study 1 applied to the current study, with the addition that participants must have 
sufficient information within their documented files to determine cocaine dependence diagnoses, 




categorization into non-dependent, psychologically-dependent, or physiologically-dependent 
groups.  
Assessment and categorization of psychological and physiological cocaine dependence  
Lifetime history of physiological and psychological cocaine dependence was diagnosed 
based on an item-level analysis of participants’ SCID-I/P (First et al., 2002). To meet the 
diagnostic criteria for physiological cocaine dependence, participants had to meet threshold 
(scored 3) for two specifiers: tolerance and withdrawal. Participants met the threshold for 
tolerance if they reported “a need for markedly increased amounts of substance to achieve 
intoxication or desired effect” or “markedly diminished effect with continued use of the same 
amount of substance” (exact wording on the SCID [Alt-E. 13, E80], refer to APA [2000], p.192). 
Withdrawal was rated based on whether the participant experienced “the characteristic 
withdrawal syndrome for the substance [i.e. fatigue, irritability, nausea]” or “the same (or closely 
related) substance is taken to relieve or avoid withdrawal symptoms” (Alt-E. 14, E88, [square 
brackets added], refer to APA (2000), p. 193). As per DSM-guidelines, participants meeting 
threshold for either tolerance or withdrawal, but not both, were categorized as Psyc-D. To be 
diagnosed with psychological dependence, participants had to meet the diagnostic threshold for 
cocaine dependence, have experienced at least one of the criteria outside of the specifiers for 
physiological dependence, and not meet threshold for both criteria for physiological dependence. 
Due to the fact that there were only 9 participants who did not meet threshold for cocaine 
dependence, but did meet threshold for cocaine abuse, they were included into the ND group for 
all analyses.  
 
 




Data analytic strategies 
 Image acquisition, preprocessing, and first-level neuroimaging analyses can be found in 
Study 1. Descriptive statistics, comparative and correlational analyses of psychometric 
behavioral results were also conducted utilizing the SPSS 24 (IBM, 2016). Second-level 
neuroimaging analyses were conducted using SPM12. We first conducted a mixed-model 
flexible-factorial analysis of variance to assess effects of Video Type (DRUG and FOOD) and 
Group (Phys-D, Psyc-D, and ND), as well as the Group*VideoType interaction, on 
hemodynamic activity while participants watched the videos. This analysis was followed by 
post-hoc within-group and between-group comparisons of hemodynamic reactivity to DRUG and 
FOOD videos.  
To assess differences between Psyc-D and Phys-D participants in terms of the effects of 
psychopathic traits and Major Drug Use on activity in the DRUG > FOOD contrast, we ran a 
multiple regression model among all dependent participants including total PCL-R scores, Major 
Drug Use, and a dummy-coded Group (Phys-D [1] and Psyc-D [0]) variable as predictors within 
the model. This model also interaction terms between the three predictors (Group*Total PCL-R, 
Group*Major Drug Use, and Total PCL-R*Major Drug Use), as well as a three-way 
Group*Total PCL-R*Major Drug Use interaction term.  
Whole-brain results were interpreted using an uncorrected threshold of .001 and a cluster 
threshold of 34 voxels (equates to a p < .05, FWE) based on a series of Monte-Carlo simulations 
run through an Alpha Simulator (AlphaSim) on the Resting-State fMRI Data Analysis Toolkit 
(REST; Song et al., 2011).  
 
 





As we predicted group-level activity differences within the same constellation of regions 
assessed in Study 1, we assessed activity within the same ROI coordinates as Study 1 in our 
Flexible-Factorial ANOVA model. Activity within the right insula (x = 40, y = -8, z = -18), left 
ACC (-6, 4, 44), left DMPFC (-5, 46, 34), right ventral striatum (11, 13, -7), left amygdala (-32, 
0, -27), and left caudate nucleus (-9, -4, 12) was assessed through small-volume corrected 
spherical search spaces. A 6mm spherical search space was used for subcortical ROIs (ventral 
striatum, amygdala and caudate) while a 10mm sphere was used for cortical ROIs (insula, ACC, 
DMPFC).  
For ROIs that demonstrated significant effects in relevant SPM models, we extracted 
parameter estimates from SPM of signal changes in response to DRUG and FOOD videos, 
relative to baseline. These parameter estimates were evaluated using multivariate analysis of 
variance (MANOVA) models and correlational models in SPSS.  
Results 
Demographics and group differences 
 Twenty participants (19.8%) met the diagnostic criteria for Phys-D, while 24 (23.8%) 
were categorized as Psyc-D, and 57 (56.4%) as ND. Interestingly, while participants were 
significantly more likely to meet the diagnostic criteria for cocaine dependence if they met the 
threshold for tolerance (n = 39, 88.6%, ()= with Yate’s continuity correction p<.001), 
participants were also more likely to be diagnosed with a cocaine dependence disorder 
(regardless of whether they were psychologically-dependent or physiologically-dependent) if 
they did not meet the diagnostic criteria for withdrawal (n = 24, 54.5%, ()= with Yate’s 
continuity correction p<.001). Moreover, while 100% of participants meeting the diagnostic 




criteria for withdrawal were categorized as Phys-D, ()= with Yate’s continuity 
correction p<.001, 48.7% of participants meeting the threshold for tolerance were categorized as 
Psyc-D, whereas the other 51.3% were categorized as Phys-D, ()= p=.091. Therefore, 
the primary distinction between both groups appears to be the experience of withdrawal. 
The sample was composed of 66 (62.3%) males, with a mean age of 35.49 (9.92); mean 
IQ of 105.71 (12.14); regularly used major drugs for 7.13 (7.97); and had a mean total PCL-R 
score of 18.48 (7.14). The sample also had a mean Factor 1 score of 6.29 (3.32) and mean Factor 
2 score of 10.93 (4.14). Group-based demographics can be found in Table 1. A multivariate 
analysis of variance was conducted to assess differences in demographics and our 
clinical/forensic variables of interest between Psyc-D, Phys-D, and ND participants. We 
observed a significant univariate effect of Group on total PCL-R scores, F(2, 98)=8.23, p<.001, 
and major drug use, F(2, 98)=33.28, p<.001, but not Age, F(2, 98)=2.18, p=.119, nor IQ, F(2, 
98)=.060, p=.942. A separate model with only Factor scores included as dependent variables 
demonstrated that another significant Group effect on both Factor 1, F(2, 98)=5.02, p=.008, and 
Factor 2 scores, F(2, 98)=6.83, p=.002. Post-hoc Bonferroni corrected t-tests demonstrated that 
both the Phys-D and Psyc-D groups had significantly higher Total PCL-R, Factor 2, and Major 
Drug Use scores than the ND group (see Table 11). In addition, the Psyc-D group had 
significantly higher Factor 1 scores relative to the ND group. There were no significant 
differences between two dependent groups on any demographic or clinical/forensic variables.  
While no significant correlations were observed, the Phys-D group exhibited a marginally 
significant correlation between Major Drug Use and age, r = .42, p = .065, while the Psyc-D 
group exhibited marginally significant correlations between PCL-R and Major Drug Use, r = .38, 
p = .064, and between Factor 2 and Major Drug Use, r = .39, p = .061 (see Table 12).  





Descriptive statistics and group-level differences in clinical/forensic variables 
Variable ND Psyc-D Phys-D t (Psyc-D > 
ND) 
t (Phys-D > 
ND) 















-.010 -.163 -.132 






5.66* 7.20* 1.66 






3.35* 3.13* .009 






2.38* 1.34 -1.03 






2.34* 3.40* 1.06 
Note. t values represent test statistic of difference between Dependent and Non-dependent 
participants. Unbracketed values represent means, while bracketed values represent standard 
deviations.  
* p (FWE)<.05 
 
Table 12 
Correlations among clinical/forensic variables within each dependence group 
 1 2 3 4 5 6 
Psychologically-dependent 
1. Age -- -.19 .42† .07 .13 .09 
2. IQ     -- -.15 .07 .08 -.04 
3. Major drug use   -- .38† .33 .39† 
4. PCL-R total     -- .91*** .91*** 
5. Factor 1      .71*** -- 
6. Factor 2       -- 
Physiologically-dependent  
1. Age -- -.39† .42† .17 .23 -.013 
2. IQ  -- -.21 -.19 .11 -.33 
3. Major Drug Use   -- .23 .13 .28 
4. PCL-R Total    -- .86*** .86*** 
5. Factor 1     -- .54* 
6. Factor 2      -- 








Sensitivity to DRUG and FOOD videos 
 We first evaluated neural reactivity to DRUG and FOOD stimuli within the three groups 
with a 3 (Group) x 2 (VideoType) mixed-factors flexible factorial ANOVA. Results are 
presented in Table 13. We observed a significant main effect of Group on activity within several 
clusters, including the right insula, left ACC, left amygdala, left dorsomedial, right medial and 
right ventromedial PFC. We also observed significant main effects of VideoType within the left 
ACC and right insula, as well as the left caudate nucleus. These main effects were influenced by 
a Group*VideoType interaction effect within the left caudate, right ventrolateral, left 
dorsolateral, and left dorsomedial PFC, and left ACC.  
In order to decipher this interaction effect, parameter estimates of regions identified to 
have a significant Group*VideoType interaction effect were entered as the dependent variable in 
a 3(Group) x 2(VideoType) MANOVA model. This analysis allowed us to assess differences in 
DRUG and FOOD reactivity relative to baseline between our three groups. While neither Group, 
F(6, 192)=.684, p = .661, nor VideoType, F(3, 96)=.957, p = .417, had significant multivariate 
main effects, there was a significant multivariate interaction effect, F(6, 192)=5.20, p <.001. 
Univariate interaction effects were observed within the left caudate, F(2, 98)=14.24, p <.001, left 
DMPFC, F(2, 98)=6.71, p =.002, and left ACC, F(2, 98)=5.99, p =.004. According to post-hoc 
Bonferroni corrected pairwise comparisons, Phys-D participants had significant greater DRUG-
related caudate activity when compared to ND, t=3.00, p = .010, and Psyc-D, t=2.69, p = .025, 
and greater FOOD-related left caudate, t=2.41, p = .053; t=2.86, p = .015, and DMPFC 
deactivation, t=2.93, p =.013; t=3.05, p = .009 when compared to the ND and Psyc-D groups, 
respectively. In addition, Phys-D participants had greater left ACC FOOD-related deactivation 
when compared to the Psyc-D group, t=2.36, p = .059, but not when compared to the ND group, 




t=1.93, p = .182. There were no significant differences between the three groups in terms of 
DRUG-related left ACC reactivity, however the Phys-D group exhibited a marginally significant 
greater deactivation of the left ACC in response to FOOD-related videos when compared to 
Psyc-D participants, t=2.37, p = .059. There were no significant differences between the Psyc-D 
and ND groups in terms of DRUG-related and FOOD-related activity. Results are visually 
depicted in Figure 3.  
Such effects were further investigated by comparing DRUG and FOOD reactivity within 
each group separately, followed by a between-group comparison of VideoType effects. Results 
are presented in Table 14. 
Within-group effects. Surprisingly, the Psyc-D group exhibited greater FOOD > DRUG 
reactivity in several clusters throughout the posterior and dorsal regions of the brain (i.e., 
occipital and parietal cortices), as well as the left caudate nucleus. The Phys-D group, in contrast, 
exhibited significantly greater DRUG > FOOD activity within the left ACC, left DMPFC, and 
right insula, while exhibiting no significant FOOD > DRUG activity throughout the brain.    
  Between-group effects. Finally, we compared DRUG > FOOD reactivity between 
groups. Phys-D participants exhibited several clusters of greater DRUG > FOOD reactivity, 
relative to the Non-dependent group. Such effects were observed within the left caudate nucleus, 
left DMPFC, and right insula. In addition, Phys-D participants also exhibited greater DRUG > 
FOOD reactivity within the left ACC, left DMPFC, and left caudate nucleus when compared to 
Psyc-D participants. Results are visually depicted in Figure 4. Another interesting observation 
was there were no significant differences between Psyc-D participants and Non-dependent 
participants in terms of DRUG > FOOD reactivity.  
 





Higher-order ANOVA results 
Region Hemi. MNI (x, y, z)    F Cluster size 
Main effect of Group 
Inferior frontal cortex L -42, 24, 0 15.51* 522 
  L -51, 12, -9 14.21*  
 Precentral gyrus L -60, 15, 21 15.37*  
Medial prefrontal cortex N/A 0, 48, 3 10.69 108 
 R 12, 51, 6 10.55  
 Ventromedial prefrontal cortex R 15, 51, -3 10.31  
Supplementary motor area L -6, -15, 63 10.46 170 
 N/A 0, -9, 57 9.78  
 Postcentral gyrus R 3, -33, 63 8.68  
Insula R 39, 18, -15 10.80† 92 
 R 39, 3, -12 8.17†  
ACC L -3, -3, 51 7.24† 57 
DMPFC L -9, 42, 24 6.39† 71 
Amygdala L -33, 0, -27 4.57† 15 
Main effect of Condition 
Superior occipital cortex R 12, -99, 12 24.60* 109 
 Middle occipital cortex R 24, -93, 0 17.49  
Caudate nucleus L -9, 18, 18 19.76* 124 
Inferior frontal cortex R 45, 21, 3 17.13 112 
 Middle occipital cortex R 33, 30, 9 12.75  
Insula R 36, 12, -9 8.59† 23 
ACC L -9, 6, 54 8.55† 28 
Interaction effect 
Caudate nucleus L -18, 9, 24 12.78* 394 
 Ventrolateral prefrontal cortex R 27, 30, 3 12.52*  
ACC L -9, 3, 36 5.50† 35 
DMPFC L -9, 45, 24 6.44† 157 
 L -9, 36, 36 6.01†  
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
ACC = Anterior cingulate cortex; DMPFC = Dorsomedial prefrontal cortex; Hemi = Cerebral 
















Differential sensitivity to DRUG and FOOD videos between groups 
 
Note. Bar-charts demonstrate differences in DRUG and FOOD reactivity between the 
Physiologically-dependent (Phys-D), Psychologically-dependent (Psyc-D), and Non-dependent 
(ND) groups. Brackets indicate significant differences at p(FWE)< .10. MRIcron images display 
intensity thresholds ranging from F = 4 – 13. Sagittal slices register to MNI coordinate x = -18 



















Within-group DRUG and DRUG neural activity 
Region Hemi. MNI (x, y, z) t Cluster size 
Psychologically-Dependent Group 
DRUG > FOOD 
No significant results     
     
FOOD > DRUG     
Middle occipital cortex L -36, -69, 6 4.05 120 
Caudate nucleus L -3, -3, 12 2.43† 13 
Physiologically-Dependent Group 
DRUG > FOOD 
Middle frontal cortex R 30, 30, 3 4.85* 1546 
Middle frontal cortex L -57, 18, 21 4.46* 151 
 Dorsolateral prefrontal cortex L -48, 42, 12 3.96  
 Postcentral gyrus L -63, -6, 30 3.67  
DMPFC N/A 0, 30, 51 3.85 165 
 L -6, 30, 42 3.82  
 Superior frontal cortex L -9, 12, 54 3.32  
Insula R 42, 18, -15 2.99† 43 
 R 39, 12, -9 2.88†  
ACC L -9, 9, 51 3.02† 161 
 L -9, 6, 36 2.71†  
 L -3, -3, 51 2.54†  
DMPFC L -3, 36, 36 3.50† 170 
 L -3, 42, 24 3.19†  
     
FOOD > DRUG     
No significant effects     
Group Differences in DRUG > FOOD 
Psychologically Dependent > Non-Dependent 
No significant effects.      
     
Physiologically Dependent > Non-Dependent  
Inferior prefrontal cortex R 30, 30, 0 4.66* 1050 
 Caudate L -15, 6, 24 4.40*  
Middle frontal cortex L -57, 21, 21 4.14 122 
 Postcentral gyrus L -63, -9, 27 3.93  
 Precentral gyrus L -57, 3, 33 3.48  
Middle frontal cortex R 45, 21, 27 3.54 171 
 R 33, 24, 24 3.47  
 Superior frontal cortex R 42, 24, 36 3.51  
Insula R 42, 18, -15 3.28† 58 
DMPFC L -3, 42, 24 3.14† 171 
 L -6, 36, 36 2.92†  




     
Physiologically Dependent > Psychologically Dependent 
Caudate nucleus L -21, 12, 21 4.93* 1982 
 Middle frontal cortex R 27, 30, 3 4.69*  
Middle frontal cortex L -60, 15, 24 4.08 117 
 Precentral gyrus L -60, 0, 30 3.94  
Postcentral gyrus R 48, -18, 24 3.68 132 
DMPFC L -6, 33, 45 3.62 183 
 L -21, 48, 21 3.57  
ACC L -9, 3, 36 3.32† 162 
 L -15, 6, 42 3.16†  
DMPFC L -9, 45, 24 3.54† 171 
 L -9, 36, 36 3.44†  
     
Non-dependent > Psychologically Dependent 
No significant results     
     
Non-dependent > Physiologically Dependent 
No significant results     
     
Psychologically Dependent > Physiologically Dependent  
No significant results     
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
DMPFC = Dorsomedial prefrontal cortex; ACC = Anterior cingulate cortex; Hemi = Cerebral 





















Note. Brain images are at a significance threshold of p(uncorr) < .001, with an extended cluster 
threshold of k =34. Slices displayed range from X=-40 to X=+50, with a X = 2mm interval 
between each slice image. Green markings identify caudate activity; red marking identify 
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Psychopathy, drug use, and DRUG > FOOD reactivity 
 According to our between-groups analyses, it appears that the neural processing bias 
towards drug- compared to food-related stimuli in substance-dependent participants is 
particularly found in physiologically-dependent participants. In fact, individuals meeting the 
criteria for psychological cocaine dependence exhibited a similar pattern of neural reactivity to 
non-dependent participants, in which case food continues to yield a greater neural response than 
drugs. We next assessed whether Major Drug Use and psychopathic traits would modulate these 
group levels differences.  
 Consistent with our previous analyses, our multiple regression analysis (see Table 14) 
demonstrated that Group had a significant main effect on DRUG > FOOD reactivity, with the 
Phys-D group exhibiting significantly greater activity within several regions, including the 
bilateral caudate nucleus, ACC, and DMPFC, as well as the right insula. While total PCL-R 
scores had no significant main effect on DRUG > FOOD reactivity throughout the brain, Major 
drug use was associated with increases in left cerebellar and left caudate nucleus activity. Group 
and Major Drug Use main effects were significantly modulated by a Major Drug Use * Group 
interaction effect within several clusters overlapping with the left ventral striatum, ACC, as well 
as the hippocampus. In addition, there were significant PCL-R*Use interaction effects within the 
cerebellum and inferior occipital cortex, however none of these effects were observed within our 
ROIs. Finally, there was a significant three-way interaction effect (PCL-R*Use*Group) on 
DRUG > FOOD reactivity within the left amygdala. By visually assessing a three-dimensional 
scatterplot (Figure 5), it appears total PCL-R scores are associated with greater DRUG > FOOD 
amygdala activity when there is also a low amount of Major Drug Use. Moreover, participants 
with higher levels of Major Drug Use exhibited a slight negative correlation between total PCL-




R scores and DRUG > FOOD reactivity within the amygdala. While this was observed in both 
groups, it appears that correlations from PCL-R scores and Major Drug Use to amygdala activity 
were more pronounced in the Psyc-D group. We conducted subsequent analyses to further 
mathematically decipher this interaction effect.  
Figure 5 
Three-way interaction between total PCL-R scores, Major Drug Use, and Group on amygdala 
reactivity to DRUG > FOOD videos 
 
Note. (A) Bain image is from a three-way interaction term (PCL-R*Group*Major Drug Use) 
from our multiple regression analysis, with total PCL-R scores, Group, and Major Drug Use 
entered as interacting predictors and DRUG > FOOD reactivity as the dependent variable. Brain 
image is set at a significance threshold of p(uncorr) < .005, with an extended cluster threshold of 
k =73. Brain image coordinate is y = 6. (B) Three-dimensional scatterplot demonstrates the 
relationship between total PCL-R scores, Major Drug Use and parameter estimates and left 
amygdala DRUG > FOOD reactivity among Phys-D and Psyc-D participants.  
To understand the nature of these interaction effects, we ran multiple regression models 
within the Phys-D and Psyc-D group independently as a means of comparing the effect of total 
PCL-R scores, Major Drug Use, and a PCL-R*Major Drug Use interaction term using the DRUG 
> FOOD contrast. Interestingly, correlations were only observed within the Psyc-D group (see 
Table 15). Total PCL-R scores were associated with increases in DRUG > FOOD reactivity 
within the left DMPFC. Analysis of parameter estimates extracted from this DMPFC coordinate 
demonstrated that Total PCL-R scores were negatively correlated with FOOD-related activity, r 
A B 




= -.66, p < .001, while also positively correlated with DRUG-related activity, r = .35, p = .095, 
with marginal significance. Major drug use, on the other hand, predicted increased DRUG > 
FOOD reactivity within the bilateral ACC, right ventral striatum and left amygdala. Analysis of 
parameter estimates demonstrated that Major Drug Use negatively correlated with FOOD-related 
activity within the right ventral striatum, r = -.66, p < .001, left amygdala, r = -.48, p = .017, and 
left ACC, r = -.43, p = .037; and positively correlated with DRUG-related activity within the 
ACC, r = .49, p = .015.  
Finally, there was a significant PCL-R*major drug use interaction effect on right insula 
DRUG > FOOD reactivity among the Psyc-D group. To understand the nature of this interaction 
effect, Psyc-D participants were separated into two sets of dichotomous groups based on median 
splits of Total PCL-R scores and Major Drug use. We correlated parameter estimates of DRUG- 
and FOOD-related signal changes relative to baseline to Total PCL-R scores among Psyc-D 
participants with high and low Major Drug Use scores (median = 10), as well as Major Drug Use 
among Psyc-D participants with high and low PCL-R scores (median = 21.53). Independent-
samples t-tests demonstrated that there were no significant differences between high and low 
Major Drug Use participants in Total PCL-R scores, t=.557, p = .584, and right insula DRUG > 
FOOD reactivity, t=1.82, p = .088. However, the high PCL-R group has significantly higher 
Major Drug Use scores, t=2.32, p = .036; greater DRUG > FOOD reactivity within the right 
insula, t=3.45, p = .002; and greater FOOD-related right insula deactivation, t=3.32, p = .003.  
Correlational analyses demonstrated that among the low PCL-R group, Major Drug Use 
positively correlated with DRUG > FOOD right insula activity, r = .83, p = .001. This correlation 
is due to a negative correlation between Major Drug Use and right insula activity, r = -.74, p = 
.006, to FOOD videos. Total PCL-R scores among the low Major Drug Use group were also 




positively correlated with right insular DRUG > FOOD reactivity, r = .64, p = .024, however 
there were no significant correlations between PCL-R scores and insula activity to DRUG, r = 
.50, p = .099, nor FOOD videos, r = -.49, p = .106. Results are visually depicted in Figure 5. 
Factors, drug use, and DRUG > FOOD reactivity 
 We then assessed which constellation of psychopathic traits, interpersonal/affective or 
lifestyle/antisocial, was primarily responsible for total PCL-R’s main effect and interaction effect 
with Major Drug Use (see Table 17). Interestingly and in contrast to regression models with 
Total PCL-R scores as a predictor, Factor score regression models only demonstrated significant 
Factor effects within the Phys-D group, and not the Psyc-D group. While no ROIs exhibited 
significant DRUG > FOOD reactivity correlating with Factor 1 or Factor 2 traits, Factor 1 traits 
did predict increased DRUG > FOOD reactivity within several clusters throughout the brain in 
Phys-D participants, including the dorsolateral PFC. Among the Psyc-D group, Major Drug Use 
predicted increase DRUG > FOOD reactivity within the bilateral ACC, ventral striatum, 
amygdala. As peak-voxel coordinates within our ROIs overlapped with our previous analyses, 
we assumed that this relationship was due to increase in DRUG-related activity within the left 
ACC and decreases in FOOD-related activity in the ventral striatum and amygdala compared to 
baseline. There were no significant interaction effects between either Factors and Major Drug 











Multiple regression results: Total PCL-R scores, Major Drug Use, Group effects on DRUG > 
FOOD reactivity 
Region Hemi. MNI (x, y, z) t Cluster size 
Group 
Positive 
Angular gyrus L -33, -57, 15 5.12* 1060 
 Caudate nucleus L -18, 3, 27 5.06*  
Precuneus R 3, -66, 39 4.14 252 
 R 21, -54, 30 3.98  
 Inferior parietal cortex R 45, -21, 27 3.95  
Middle frontal cortex R 30, 24, 24 3.88 104 
 Caudate nucleus R 18, 0, 27 3.77  
 Putamen R 27, 12, 12 3.56  
ACC L -9, 3, 36 3.19† 138 
 L -15, 6, 42 3.13†  
DMPFC L -9, 48, 24 3.51† 171 
 L -6, 54, 33 3.39†  
 L -9, 36, 33 3.14†  
 L -3, 45, 42 3.02†  
     
Negative     
No significant results     
PCL-R 
No significant results 
Major Drug Use 
Positive 
Caudate nucleus L -6, 0, 9 2.55† 16 
     
Negative     
No significant results     
Interaction effects 
PCL-R * Group     
No significant results     
     
Major Drug Use * Group     
Cerebellum R 24, -57, -27 5.11* 240 
 R 39, -48, -36 4.22  
 R 27, -36, -36 4.15  
Amygdala/parahippocampal gyrus L -21, -9, -9 4.88 152 
 Hippocampus L -33, -24, -9 4.38  
 L -27, -21, -24 3.47  
Middle cingulate cortex L -3, -6, 24 4.77 199 
 ACC L -3, 12, 24 4.59  
Parahippocampal gyrus R 18, -27, -15 4.12 110 




Inferior occipital cortex R 33, -78, -6 4.31 105 
     
PCL-R * Use     
Cerebellum R 30, -57, -33 4.82 127 
     
PCL-R * Use * Group     
Amygdala L -33, 6, -27 2.63† 31 
 L -30, -3, -30-33 2.43†  
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
ACC = Anterior cingulate cortex; DMPFC = Dorsomedial prefrontal cortex. Hemi = Cerebral 
Hemisphere; MNI = X, Y, Z coordinates on a Montreal Neurological Institute template. 
 
Table 16 
Multiple regression results: Total PCL-R scores, Major Drug Use, and DRUG > FOOD-related 
hemodynamic activity among the Psyc-D group 
Region Hemi. MNI (x, y, z) t Cluster size 
PCL-R 
Positive 
DMPFC L -9, 51, 39 4.01† 126 
     
Negative     
No significant results     
Major Drug Use 
Positive 
Parahippocampal gyrus R 24, -30, -21 5.97* 129 
Hippocampus L -33, -27, -6 4.89 188 
 Fusiform gyrus L -18, -45, -21 4.31  
 Parahippocampal gyrus L -27, -27, -24 4.10  
ACC L -3, 0, 36 2.81† 70 
Ventral striatum R 9, 9, -3 2.81† 28 
Amygdala L -36, 3, -30 2.38† 7 
     
Negative     
No significant results     
PCL-R * Major Drug use 
Cerebellum R 27, -57, -36 5.21 111 
 R 36, -69, -42 4.22  
Insula R 39, -12, -21 3.66† 108 
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
ACC = Anterior cingulate cortex; DMPFC = Dorsomedial prefrontal cortex. Hemi = Cerebral 
Hemisphere; MNI = X, Y, Z coordinates on a Montreal Neurological Institute template. 
 





Multiple regression results: Factor scores, Major Drug Use, and DRUG > FOOD-related 
hemodynamic activity among the Psyc-D group 
Region Hemi. MNI (x, y, z) t Cluster size 
Physiologically Dependent 
No significant results      
Psychologically Dependent 
PCL-R Factors 
No significant results  
 
Major Drug Use     
Positive     
Parahippocampal gyrus R 24, -30, -21 5.95* 147 
 R 15, -27, -12 3.86  
ACC R 9, 15, 27 5.39 106 
 R 3, 6, 30 4.94  
 R 15, 3, 33 4.48  
Hippocampus L -33, -27, -6 4.92 203 
 Cerebellum L -21, -48, -21 4.54  
 Parahippocampal gyrus L -27, -30, -21 4.26  
ACC L -3, 0, 36 2.95† 95 
Ventral striatum R 9, 9, -3 2.93† 31 
 R 6, 12, -6 2.85†  
 R 15, 15, -9 2.34†  
Amygdala L -36, 3, -30 2.47† 8 
 L -33, 0, -33 2.46†  
     
Negative     
No significant results     
All regions show significant activity at p(uncorr) < .001; * p(FWE) < .05; † p(svc-FWE) <.05; 
ACC = Anterior cingulate cortex; DMPFC = Dorsomedial prefrontal cortex; Hemi = Cerebral 














We looked to further understand the neural processing bias towards drug-related rewards 
relative to non-drug rewards by assessing differences in this neural processing bias between 
participants who were physiologically-dependent and psychologically-dependent to cocaine. We 
demonstrated that this neural processing bias varies as a function of the type of substance 
dependence. In this case, participants with a physiological cocaine dependence, characterized by 
use-promoting behavioural dysfunctions and symptoms of tolerance and withdrawal, exhibited a 
significantly greater neural processing bias towards drug-related videos relative to food videos 
compared to both psychologically-dependent, characterized by use-promoting behavioural 
dysfunctions alone, and non-dependent participants. In fact, psychologically-dependent 
participants exhibited no significant difference in drug-related neural reactivity relative to non-
dependent participants and exhibited the same pattern of activation in response to food-related 
content as non-dependent participants.  
Specifically, physiologically-dependent participants exhibited greater reactivity to drug-
related stimuli within the ACC, ventral striatum, amygdala, DMPFC, and caudate nucleus when 
compared to non-dependent participants. The ACC has been found to underlie attentional biases 
towards drug-related stimuli (Goldstein et al., 2007; Luijten et al., 2011), which has been found 
to predict relapse into substance use (Marhe, Luijten, van de Wetering, Smits, & Franken, 2013). 
The ventral striatum has been thought of as a corticolimbic interface underlying motivational 
salience of drug-related stimuli, integrating visuospatial and incentive salience of drug-related 
stimuli and, and promoting drug-seeking behavior (Floresco, 2015; Ikemoto & Panksepp, 1999; 
McFarland, Lapish, & Kalivas, 2003; Salamone, Correa, Mingote, & Weber, 2005; Weiss, 
2005). The caudate has been found to underlie stimulus-reinforcement learning and the 




development of habitual drug-seeking behaviour (Ito, Dalley, Robbins, & Everitt, 2002; Koob & 
Volkow, 2010; Murray et al., 2014, 2015; Vollstädt-Klein et al., 2010; Weiss, 2005; Yin, 
Ostlund, Knowlton, & Balleine, 2005). The amygdala plays a pivotal role in salience attribution 
and salience sensitization of drug-related stimuli, particularly following withdrawal (Ding et al., 
2013; Lee et al., 2013; Murray et al., 2015). Finally, the DMPFC has been found to underlie 
drug-seeking behavior by guiding decision-making in a biased manner, leading to goal-directed 
behavior to be the sum of drug-related sensori-information integration and focused only on 
obtaining a drug-reinforcer (Jasinska, Chen, Bonci, & Stein, 2015). Therefore, physiologically-
dependent participants may exhibit greater drug-related dysfunction within these areas, leading 
to a greater attentional, saliency, and motivational bias towards drug-related stimuli. This could 
then translate to a higher drug-related neural processing bias in physiologically-dependent 
participants relative to non-dependent and psychologically-dependent participants, substantiating 
our results.   
Importantly, these results also indicate that the distinction between psychological and 
physiological dependence should no longer be ignored. For instance, our findings of greater 
neural dysfunction within physiologically-dependent participants is consistent with psychometric 
studies demonstrating a greater number of health-related and psychosocial problems in the daily 
lives of individuals with a physiological dependence to a substance (Lejoyeux et al., 2001; 
Schuckit et al., 1998, 1999, 2003). Combining psychological and physiological dependence into 
a single substance dependence category may reduce the validity of the assessment in diagnostics 
and research by ignoring the moderating effect of dependence-category, and therefore ignoring 
the behavioral and neural differences that significantly distinguish these categories. Indeed, 
while DSM-IV-TR nosology is no longer commonly used, experts diagnosing SUDs using the 




DSM-5 have called for an investigation of further differences of physiologically-dependent 
individuals relative to other substance user groups (Blanco et al., 2017). This study demonstrated 
that physiologically-dependent individuals can be separated from other substance-user groups, 
including but perhaps not limited to psychologically-dependent individuals, based on functional 
neural features that raise the possibility of further drug use. Future studies in addiction should 
consider separating their substance-dependent/substance user groups into physiologically-
dependent and either psychologically-dependent or another term that distinguishes between 
participants with a substance use disorder characterized by behavioral and physiological 
symptoms and participants with only dysfunctional behavioral symptomology. This could 
increase the external validity of their results to generalize to real-world scenarios and 
populations. 
This is the first study to investigate abnormalities in the neural processing of drug- and 
non-drug reward in physiologically- and psychologically-dependent participants separately, 
rather than combining both in a single dependent category. Moreover, this is the first study to 
demonstrate that only physiologically-dependent individuals exhibit the neural processing 
abnormalities noted as distinctive factors of drug addiction within the i-RISA model (Goldstein 
& Volkow, 2002, 2011). The i-RISA model hypothesizes that individuals with an addictive 
disorder fail to inhibit further hazardous substance use due to a saliency bias towards drug-
related rewards relative to non-drug rewards, particularly due to a combination of severe drug 
use and periods of drug withdrawal. Studies have previously demonstrated a preference for drug-
related relative to non-drug rewards (Study 1; Garavan et al., 2000; Goldstein et al., 2009; 
George et al., 2001), and demonstrated increased drug-related reactivity (relative to a neutral 
control condition) following/during drug withdrawal in overlapping neural regions (Jasinska et 




al., 2014; Lou et al., 2012; McClernon et al., 2005, 2009). However, no study has assessed the 
distinction between physiologically-dependent and psychologically-dependent participants in 
terms of the neural processing of drug- and non-drug rewards, and therefore, we further support 
the i-RISA model by demonstrating that this processing bias towards drug-related rewards is 
only found among participants that experienced symptoms of tolerance and withdrawal.  
  Importantly, the above effect occurred despite there being no significant difference in the 
level of substance use between participants who were physiologically and psychologically 
dependent to cocaine. Moreover, as the only significant difference between participants with 
either form of dependence whether they had experienced withdrawal symptoms following use-
cessation, we can carefully speculate that the neural processing bias in substance-dependent 
individuals may be primarily due to withdrawal. This is consistent with theoretical models of 
addiction that hold that withdrawal has a pivotal role in the incentive sensitization process of 
drug-related stimuli and facilitation of compulsive drug use (Koob, 2010, 2017; Koob & Le 
Moal, 1997; Koob & Volkow, 2010; Wise & Koob, 2014). In addition, while also being closely 
consistent with other empirical studies demonstrating increased drug-related reactivity 
following/during drug withdrawal in overlapping neural regions (Jasinska et al., 2014; Lou et al., 
2012; McClernon et al., 2005, 2009), this study may also provide the first empirical evidence 
that withdrawal plays a strong faciliatory role in the development of a bias towards drug-related 
rewards, as hypothesized by the i-RISA model (Goldstein & Volkow, 2002, 2009). Therefore, 
withdrawal may play a faciliatory role in creating this neural processing bias towards drug-
related rewards and an inability to resort to other forms of reward to satiate hedonic needs.  
Interestingly, substance use only had an effect among psychologically-dependent 
participants, such that increases in the number of years regularly using major drugs increased the 




magnitude of the drug > food bias, while no effect was observed among the physiologically 
dependent group. This is interesting considering psychologically-dependent participants 
normally exhibit a similar activation pattern to food-related relative to drug-related stimuli as 
non-dependent participants. However, it appears that with increasing levels of regular drug use, 
psychologically-dependent participants may begin to exhibit the dysfunctional neural processing 
bias as physiologically-dependent participants. It is possible that with increasing drug use, 
psychologically-dependent participants will begin to show a neural-reactivity preference for 
drug-related rewards relative to non-drug rewards, which reaches its greatest and most 
devastating magnitude once they experience both tolerance and withdrawal, and therefore, 
qualify as physiologically-dependent. 
 The effect of substance use was observed through an increase in ACC drug-related 
reactivity and decrease in food-related reactivity within the ventral striatum, amygdala, and 
ACC. Considering the ACC has been commonly reported to underlie attentional biases towards 
drug-related stimuli (Goldstein et al., 2007; Luijten et al., 2011), it appears that increases in 
substance use may facilitate the development attentional biases to drug-related stimuli among 
psychologically-dependent participants. Moreover, the effects on the ventral striatum, which has 
been noted to promote drug-seeking behavior with increasing substance use (Floresco, 2015; 
Weiss, 2005), suggests that increasing substance use may further bias the ventral striatum into 
promoting drug-seeking behavior in response to drug-related cues. Finally, the effects on the 
amygdala, which has been noted to play a role in salience misattribution (Ding et al., 2013; Lee 
et al., 2013; Murray et al., 2015), suggests that increasing substance use may lead to this 
amygdalar dysfunction that results in a greater amount of incentive salience being attributed to 
drug-related stimuli relative to non-drug rewards. By affecting these drug-related neurocognitive 




factors, continued regular substance use may promote an inability to resort to non-drug related 
rewards to satiate hedonic needs by increasing the neural processing bias to drug- compared to 
non-drug rewards in psychologically-dependent participants, which may promote further drug 
use, and make cessation of use all the more onerous by eventually leading to physiological 
dependence (i.e. withdrawal symptomology). As a result, these psychologically-dependent 
participants would eventually develop the most extreme magnitude of this neural processing bias 
as they become physiologically-dependent to the substance. Future research should investigate 
whether the transition from psychological- to physiological-dependence is as linear as stated 
above, or whether these categories may not be placed on a linear continuum. 
Finally, psychopathic traits were also found to modulate the drug > food processing bias. 
Psychopathic traits were associated with an increased neural processing bias to drug relative to 
food stimuli in the DMPFC in psychologically dependent participants, and similarly to substance 
use severity, no effect was observed among physiologically-dependent participants. This 
suggests that psychopathic traits may have a similar effect as substance use, in which case they 
may be associated with a potentially accelerated development of a neural processing bias 
towards drug-related stimuli among psychologically-dependent participants that could render 
drug-use increasingly difficult to abstain, and potentially, facilitating the development of a 
physiological substance dependence. With psychopathy being associated with reduced gray 
matter volume within the DMPFC (Cope et al., 2012), it is possible that pre-existing 
psychopathy-related neural abnormalities predispose individuals to a sensitized drug-related 
goal-directness in their decision-making, the neurocognitive factor that to be supported by the 
DMPFC (Jasinska et al., 2015). This may predispose such individuals to further complications 
with substance abuse, leading them into the vicious cycle of addiction similar to how increased 




substance use severity may increase the odds of psychologically dependent individuals 
developing a physiological dependence through neural processing changes. This may therefore 
be an explanation for how psychopathic traits are comorbid with SUDs, as they are more 
prevalent among psychological and physiological dependent participants and could potentially 
increase neural processing abnormalities in psychologically dependent individuals to levels 
similar to physiologically dependent individuals.  
Psychopathic traits also exhibited an interaction effect with substance use severity within 
the insula, a region known to be associated with interoceptive reward-processing in addiction 
(Koob & Volkow, 2016; Naqvi & Bechara, 2009, 2010). Interesting, this was a similar pattern as 
noted in Study 1. Among individuals with a low level of psychopathic traits, major drug use 
positively correlated with increased drug > food reactivity, whereas there was a non-significant 
relationship between major drug use and drug > food reactivity in high psychopathy 
psychologically dependent participants. In fact, there was a slight downwards trend in the high 
psychopathy group, with an extensive major drug use history being associated with a reduced 
neural processing bias to drug- relative to non-drug rewards. This raises further question about 
the effect of psychopathy in this psychologically dependent group. While certain regions and 
certain processes are sensitized by psychopathic traits (i.e. DMPFC-related processes), which 
may translate to a sensitized neural processing bias, other processes may become desensitized 
with increasing drug use and psychopathic traits. It appears that insula drug > food reactivity, 
possibly due to changes in interoceptive reward-processing, undergoes a desensitization in highly 
psychopathic individuals as their substance use severity increases. This may further our 
understanding of previous reports on the relationship between psychopathy and drug-stimulus 
processing (i.e. Cope et al., 2014; Vincent et al., 2017), by demonstrating that decreases in neural 




reactivity to drug-stimuli in highly psychopathic individuals may be the result of an interaction 
between psychological substance dependence accompanied by a high level of substance use and 
a high level of psychopathic traits with no indication of physiological dependence.  
The fact that only effects of substance use and psychopathic traits, and an interaction 
effect, were observed within psychologically-dependent participants, while there were no 
differences in psychopathic traits and substance use severity between groups, suggests that other 
factors may be promoting this neural processing bias. It is possible that psychopathic traits and 
substance use severity exhibit a ceiling effect within this subgroup of substance dependent 
individuals, and that other factors may be playing a greater role in this neural processing 
abnormality. Considering withdrawal-experience was the only variable that differed between 
these two groups, one could speculate that withdrawal may play a substantial role in the neural 
processing bias severity, and future studies should investigate, using neuroimaging methods, 
whether this hypothesis is correct.  
Finally, we did observe effects within the physiologically dependent group of 
interpersonal/affective psychopathic traits on this drug-related neural processing bias, notably in 
the dorsolateral prefrontal cortex. The dorsolateral prefrontal cortex, although not an ROI, has 
been found to be involved in drug-related neural reactivity relative to a non-drug reward control 
condition (George et al., 2001). Interestingly, the dorsolateral prefrontal cortex has also been 
found to be a reliable target of neurostimulation to reduce cue-induced craving sensations in 
addiction (Conti & Nakamura-Palacios, 2014; Li et al., 2013). This structure, with its numerous 
inputs to the limbic regions including the ventral striatum, is thought to select contextual 
information appropriate to the individual’s goals and may further potentiate the biased-goal 
directness of other regions (i.e. DMPFC) in individuals with a SUD and regulate inhibitory 




control in response to cues (Feil et al., 2010). Interpersonal/affective psychopathic traits may be 
associated with the more biased selection of drug-related contextual information to motivate 
one’s goal-directed behaviour in concordance with abnormalities in the ACC, DMPFC, and 
limbic regions.  
These results may have a practical implication for the diagnosis of SUDs and the 
definition of addiction. Analyses support the idea of a spectrum of addiction, in which case a 
neural processing bias towards drug-related stimuli compared to non-drug rewards may be found 
in the most severe forms of addiction accompanied by physiological factors of dependence. 
Moreover, these severity levels could also be separated by the contribution of individual 
differences, such as psychopathic personality traits, and patterns of major substance use. Future 
studies should assess what other factors, be them behavioral, cognitive, personality-related, 
social or biological, further separates these levels of addiction, and whether a substantial 
distinction between these two forms of dependence have value despite their no-longer inclusion 
in the DSM. In addition, these results raise question about the role of psychopathic traits in the 
severity-levels of other externalizing behaviors and comorbid mental disorders. In addition, 
while psychopathic traits were at similar levels between psychologically dependent and 
physiologically dependent participants, studies should assess whether psychopathic traits could 
be a contributing factor to understanding other mental disorders and developing more accurate 
diagnostic measures utilizing psychopathic traits.  
Limitations 
 One obvious limitation with our study is the size of the psychologically- and 
physiologically-dependent participants, which were less than half the size of the non-dependent 
group. This may have affected the statistical power of the study, which may have precluded the 




ability to observe smaller effect sizes at a significant threshold. In addition, this study was 
conducted only among an offender sample, who are known to have higher estimates of substance 
use severity and psychopathic traits (CCSA, 2004; Hare, 2003). Therefore, it is possible that the 
distribution of psychopathic traits and substance use patterns does not reflect what we would 
observe in the general population, limiting the external validity of our neuroimaging results to 
healthy non-offending individuals. Future studies should investigate this phenomenon among the 
general population, assessing the influence of substance use severity and psychopathic traits on 
neural reactivity to drug- and non-drug rewards in psychologically- and physiologically-
dependent participants.  Finally, very few of our participants would be diagnosed officially as 
psychopathic, as it is typically required to achieve a PCL-R score of 30 to be considered 
psychopathic (Hare, 2003), and the highest PCL-R score within our sample was 34. However, 
there is a large body of research demonstrating that psychopathy is a dimensional disorder that 
can be conceptualized as a spectrum rather than through a categorical and dichotomized 
















 The first goal of this thesis was to investigate abnormalities in drug- and food-related 
stimulus processing in the brain of individuals with a substance dependence disorder. We 
demonstrated a neural processing bias towards drug-related stimuli compared to food-related 
stimuli within a corticolimbic circuit consisting of reward-processing, salience attribution and 
decision-making regions, including the insula, DMFC, amygdala, ventral striatum, and ACC. 
Next, we compared this neural processing bias between two variants of substance dependence: 
physiological and psychological dependence and demonstrated that this neural processing bias is 
found only in physiologically dependent participants. This was the first time that neural 
processing of drug-related stimuli was assessed in subcategories of substance dependent 
individuals, and therefore the first body of work demonstrating differences between 
physiologically- and psychologically-dependent individuals in functional neurological factors. 
 The second goal of this thesis was to further understand the comorbidity between 
psychopathic traits and addiction by investigating the relationship between psychopathic traits 
and drug- and food-stimulus processing, and how this interacted with the severity of one’s 
substance use.  We demonstrated a significant role of psychopathic traits on this neural 
processing bias towards drug-related stimuli, such that psychopathic traits sensitized the neural 
processing bias to drug-related rewards in substance dependent individuals. Interestingly, 
psychopathic traits were also found to modulate the effect of substance use on this bias, with 
individuals with the highest level of psychopathic traits exhibiting a decrease neural processing 
bias as substance use severity increased. What is interesting is that the effect of psychopathic 
traits was modulated by whether the individual was psychologically- or physiologically-




dependent to the substance, such that psychopathic traits were only found to have a main effect 
and an interaction effect with substance use among psychologically-dependent participants. 
While studies have previously assessed the relationship between psychopathic traits and drug-
stimulus processing in the brain relative to a neutral control (Cope et al., 2014; Vincent et al., 
2017), this was the first body of work investigating the relationship between psychopathic traits 
and the neural processing of drug-related rewards compared to non-drug rewards; the modulating 
effect of psychopathic traits on substance use-mediated neural processing abnormalities; the 
effect of psychopathic traits and neural reactivity in both dependent and non-dependent 
participants; and the effect of psychopathy in psychologically- and physiologically-dependent 
participants as individual and separate categories of substance dependence.  
 The results of this thesis have several implications for our understanding of addiction, 
including contributions to contemporary models of addiction, and how psychopathic traits affect 
the development and maintenance of addiction. These implications will be explored individually 
throughout these remaining subsections.  
Evidence for the i-RISA and three-stage models of addiction 
 The results of this thesis have fundamental implications for our understanding of 
addiction, as they provide support for the contemporary Impaired Response-Inhibition and 
Salience Attribution model of addiction (i-RISA; Goldstein & Volkow, 2002). The i-RISA 
model holds that drug-related stimuli will be more salient and stimulating than non-drug-related 
stimuli, which would make drug-use increasingly difficult to abstain. This thesis, in addition to 
other studies demonstrating a drug-reward relative to non-drug reward processing bias (Garavan 
et al., 2000; George et al., 2001; Goldstein et al., 2009), substantiated this model by 
demonstrating that individuals with a substance dependence disorder exhibit a neural processing 




bias towards drug-related stimuli relative to non-drug rewards. In addition, as we observed a 
neural processing bias within cortical regions (i.e. anterior cingulate cortex, dorsomedial 
prefrontal cortex), this further supports the localized hypotheses of the i-RISA model that 
dysfunction within the prefrontal and anterior cingulate cortices underlie this neural processing 
bias in individuals with an addiction (Goldstein & Volkow, 2002; Goldstein et al., 2011).  
The results of this thesis offer support for the three-stage model of addiction. This theory 
holds that individuals develop a compulsive and uncontrollable need to use a substance by 
cycling through three-stages: binge/intoxication, withdrawal/negative affect, and 
craving/preoccupation (Koob & Le Moal, 1997, 2005, 2008a, 2008b). Moreover, this model 
suggests that neuroplastic changes occurring throughout this cycle makes drug-related stimuli 
increasingly salient and addiction increasingly severe. In addition to demonstrating that 
physiologically-dependent participants were the only ones to exhibit this neural processing bias, 
physiologically-dependent participants were the only one’s to report experiencing withdrawal, 
while tolerance (the other physiological dependence specifier) was equally reported by both 
physiologically- and psychologically-dependent participants. Therefore, we can speculate that 
withdrawal may have sensitized this neural processing bias towards drug-related rewards relative 
to non-drug rewards. Not only is this hypothesis consistent with the three-stage model of 
addiction, but it is also consistent with another tenet of the i-RISA model, which holds that drug-
related stimuli gains greater salience than non-drug rewards by cycling through these three stages 
of addiction (Goldstein & Volkow, 2002, 2011). Individuals with a physiological dependence 
may be distinct from psychologically-dependent individuals due to their experience of drug-
withdrawal following use cessation, in addition to heavy drug use, which may lead to 




neuroplastic changes that facilitates the most severe magnitude of this neural processing bias, 
and potentially, the greatest difficulty in abstaining from further drug use.  
Evidence for an addiction-severity model 
 These results have implications for further understanding addiction, and the development 
of a more comprehensive and complete model of addiction that reconciliates 1) the DSM and 
other contemporary models of addiction, and 2) opposing camps within the field of addiction 
research. The three-stage model of addiction has been criticized for placing such a large 
emphasis on the role of withdrawal in addiction, with such critics holding that addiction develops 
sooner and independently of withdrawal (Wise & Koob, 2014). On this premise, Roy Wise 
(Wise & Koob, 2014) criticized those using physiological dependence as synonymous to 
addiction. This camp of addiction research hold addiction is due to the strong positive 
reinforcement properties of drug-reward, and that dopamine reactivity to drug-related stimuli 
will lead to compulsive drug use and addiction (Wise, 1988; Wise & Koob, 2014).  
However, George Koob argued that he, himself as the author of the three-stage model of 
addiction, was not disregarding the role of positive reinforcement in addiction and held that 
positive reinforcement was the initial catalyst of the development of addiction (Wise & Koob, 
2014). The role of withdrawal, according to this contrasting camp of addiction research, is that is 
may lead to addiction becoming more severe, more difficult to extinguish, and predict 
increasingly worse prognoses (Wise & Koob, 2014). Essentially, early neurobiological changes 
in the brain as a result of drug use, including changes in dopamine receptor availability in the 
mesocorticolimbic reward pathway, will catalyze the development of addiction, while changes as 
a result of the allostatic antireward system activation will lead to more profound neurocognitive 
dysfunctions, drug-seeking behavior and more profound inability to cease use (Di Chiara, 1998; 




Koob & Le Moal, 2005, 2008a, 2008b; Koob & Volkow, 2010; Robinson & Berridge, 1993, 
2000; Wise & Koob, 2014).  
Withdrawal is hypothesized to lead to neuroplastic changes, particularly within the 
amygdala, ventral striatum, and cortical regions, that underlie profound drug-related incentive 
sensitization, and would ultimately lead to the deficits not only found within the current thesis 
but noted as central within the i-RISA model (Goldstein & Volkow, 2002, 2011; Koob & 
Volkow, 2010). An empirical example of such a phenomenon is an animal-based study by Lee et 
al. (2011). Rats were repeatedly administered cocaine, which was associated with synaptogenesis 
between amygdala and ventral striatum neurons, however these synapses were considered 
“silent-synapses” due to their inactivity. After no longer having access to cocaine, the rats 
underwent a withdrawal syndrome. Following withdrawal, these silent-synapses became active, 
and were associated with increased drug-seeking behavior in response to a cocaine-related cue 
and cocaine craving within the rats. When blocking withdrawal, these silent-synapses failed to 
activate, and changes in cocaine-related incentive salience were blocked. While this was an 
isolated study with a singular focus on connections between amygdalar and ventral striatal 
neurons, it is theorized that neuroplastic changes extend to cortical regions as well following 
periods of heavy drug use and drug withdrawal, which underlies i-RISA related dysfunctions.  
Koob (2009, 2013, 2017; Koob & Le Moal, 1997, 2005, 2008a; Koob & Volkow, 2010) 
holds that withdrawal will lead to more severe forms of addiction as he claims that antireward 
systems (amygdala and bed nucleus of the stria terminalis) become increasingly sensitized to 
denote an increasingly severe withdrawal syndrome, which will then promote further drug use 
and a more severe addiction. Based on the opponent process model (Solomon & Corbitz, 1974, 
1980), Koob theorizes that reward, known as process A, will raise the mind’s hedonic arousal to 




a peak, and process B, known as withdrawal, will be a neurological mechanism that will return 
the brain to a hedonic baseline (Koob, 2017; Koob & Le Moal, 1997). He posits that the A 
process will become increasingly lower in peak levels, which denotes a growing tolerance to the 
effects of the drug. The B process, on the other hand, will become increasingly stronger and 
more severe, essentially denoting that withdrawal is becoming increasingly severe. Hence, 
withdrawal becomes increasingly more severe, the motivation to use a drug extends beyond 
simply wanting reward but also a growing desire to end the negative affect accompanying drug-
abstinence. As a result, drug use becomes ever more compulsive, difficult to cease, and addiction 
is at its most severe form.    
While the results of this thesis do not specifically support the latter camp of addiction 
research in terms of the pivotal role of withdrawal, one can suggest of how DSM substance 
dependence subcategories may relate and perhaps reconcile this debate within the field based on 
the observations within this thesis. It is possible that physiological dependence may not be 
interchangeable with the term ‘addiction’, but may denote a more severe form of addiction, 
similar to Koob’s position on the role of withdrawal and negative reinforcement in addiction 
(Wise & Koob, 2014). Essentially, the DSM distinction between psychological and physiological 
dependence may help distinguish various severity levels of addiction from mild to severe. 
Psychological dependence may be an earlier and milder form of addiction, in which case there is 
an incentive sensitization of drug-related stimuli, and a decrease in the reward-response from the 
drug. Physiological dependence represents a severe form of addiction, characterized by drug-
related incentive sensitization, non-drug related incentive desensitization, increased negative 
affect and withdrawal in abstinence periods, heightened craving, and an increasing tolerance to 
the drug’s rewarding effects.  




When considering the results of the current thesis, psychological dependent subjects 
exhibited a more severe drug-use pattern and behavioral dysfunctions relative to non-dependent 
subjects. Therefore, we can suggest that psychological-dependence is an early and milder form 
of addiction based on these results. Moreover, as they used more and more substances at a 
regular rate, they began to exhibit a preference in neural systems for drug-related rewards 
compared to non-drug rewards. Physiologically-dependent participants demonstrated a similar 
substance use pattern as psychologically-dependent participants that was more severe than non-
dependent subjects. What distinguished physiologically-dependent participants was the neural 
processing bias towards drug-related stimuli relative to non-drug stimuli. Therefore, it could be 
suggested that physiological dependence is a more severe form of addiction than psychological 
dependence, characterized by behavioral dysfunctions with the neural processing bias that may 
facilitate a more severe and compulsive addictive substance use pattern and increasingly worse 
prognoses for the individual. As psychologically-dependent participants use more and more 
substances, they would start to exhibit physiological-dependence symptoms, concomitant with 
increasing neurocognitive dysfunctions that underlying the distinction of psychological and 
physiological substance dependence. There addiction would thus be at its most severe form, and 
prognoses would become ever-more negative.  
Combining DSM-categorizations with other contemporary models of addiction, I propose 
the following comprehensive model of addiction. In accordance with the continuum theory by 
Everitt and Robbins (2016), individuals transition from an impulsive to a compulsive pattern of 
drug use that is increasingly uncontrollable. They transition through this continuum is initialized 
by the positive reinforcement of drug use, consistent with dopamine-based theories of addiction 
(Di Chiara, 1998; Wise, 1988), which will facilitate the development of a psychological 




dependence to the drug. Concomitantly, there will be a sensitization the incentive salience of 
drug-related cues, consistent with the incentive sensitization hypothesis (Robinson & Berridge, 
1993), as well as a growing tolerance to the neurochemical effect of the drugs that lead to 
reward. The individual will then transition from psychological to physiological dependence by 
cycling through three-stages: binge/intoxication, abstinence, and craving, taken directly from the 
three-stage model of addiction (Koob & Le Moal, 1997). As the individual cycles through these 
stages, the stages will begin to change, and the individual will begin to experience withdrawal 
following cessation of drug use rather than simply abstinence (Koob & Le Moal, 1997, 2005, 
2008a; Koob & Volkow, 2010). The individual will then become physiologically-dependent to 
the substance, repeatedly cycling through the binge/intoxication stage, withdrawal/negative 
affective stage, and craving/preoccupation stage. These stages will become increasingly severe 
with repeated cycles of these addiction stages, leading to a sensitized antireward system and 
withdrawal syndrome (Koob, 2017; Koob & Le Moal, 2008a; Koob & Volkow, 2010). The 
individual will begin to develop neurocognitive abnormalities supporting further drug use, 
including further drug-related incentive sensitization, non-drug-reward incentive desensitization, 
and a neural processing bias towards drug-related relative to non-drug rewards, consistent with 
the i-RISA model (Goldstein & Volkow, 2002, 2011). Drug use will become increasingly 
difficult to resist, rendering individuals in the physiological dependence stage of the addiction 
spectrum to exhibit the most compulsive form of drug use, and therefore, the most severe form of 









Contemporary model of addiction: Transition from impulsive to compulsive use. 
 
Note. Adapted from to contemporary addiction models and associated figures in Koob & Le 
Moal (1997), Robinson & Berridge (1993), Everitt and Robbins (2005), and Goldstein & 
Volkow (2002), with an added distinction in the role of physiological and psychological 
dependence. Individuals transition from impulsive use to compulsive use by repeatedly using the 
drug, and the positive reinforcing effects sensitize the incentive salience of the drug-reward, 
while also creating a tolerance due to allostatic mechanisms. As the individual continues to use 
the drug, abstinence becomes associated with withdrawal which intensifies with repeated cycles 
of the addiction. This leads to a continuous sensitization of the antireward system and 
desensitization of the reward systems. In addition, the incentive salience of non-drug rewards 
decreases, which creates a reward and motivational bias towards drug- compared to non-drug 












The contemporary and integrative model proposed above uses categories defined by the 
American Psychiatric Association (APA, 2000) in the fourth edition of the DSM. Such a model 
could thus be communicated and advocated to clinicians to consider when they made their 
assessment of substance users, in order to develop a treatment program tailored towards the 
severity of their addiction disorder. Separating the addiction spectrum according to DSM 
categories may help clinicians be able to distinguish levels of addiction severity, which may have 
practical implications on treatment efficacy. However, while these DSM categories served our 
purposes for the current thesis, and participants were previously assessed using the DSM-IV-TR 
(DSM edition corresponding to the SCID-I/P; First et al., 2002), the current version of the DSM 
(DSM-5) no longer separates participants based on dependent or non-dependent, nor are 
substance users separated based on physiological or psychological dependence (APA, 2013). 
Rather, the DSM-5 combined diagnoses of substance abuse and substance dependence disorders 
into one broad category: substance use disorder. The fact that we demonstrated differences 
between physiologically- and psychologically-dependent participants raises question about the 
DSM-5 diagnostic criteria, the accuracy of such diagnoses, and whether specifying SUD 
diagnoses according similar to the DSM-IV-TR could yield greater prognostic validity. While 
distinguishing between abuse and dependence may lack incremental value, a different 
categorization may yield more positive outcomes, one that does not ignore the behavioral and 
neurological differences between psychologically-dependent and physiologically-dependent 
individuals. One solution is to return to the separation of psychological and physiological 
dependence, however other options have been suggested prior to the release of the DSM-V, such 
as the the Withdrawal-Gate Model (Langenbucher et al., 2000) and the separation of 
physiological substance dependence from a new terminology of psychological dependence: 




substance dyscontrol disorder (Widiger & Smith, 1994). Regardless, there should be 
investigation as to whether separating dependence disorders may be a more clinically appropriate 
solution compared to DSM-5 SUD diagnoses.  
Psychopathic traits and individual differences in predisposition for addiction 
  The second aim of this thesis, in which case we targeted the effect of psychopathic traits 
on this drug-stimulus processing bias, was primarily to reconciliate psychometric research on the 
relationship between psychopathic and SUDs and functional neuroimaging research on 
psychopathic traits and drug-stimulus processing. While our results further explain the 
comorbidity between psychopathic traits and substance dependence, they did somewhat counter 
studies by Cope et al. (2014) and Vincent et al. (2017), who both found that psychopathic traits 
were associated with decreases in drug-cue reactivity within corticolimbic regions when 
compared to a neutral cue. We found that the nature of the relationship between psychopathic 
traits and drug > food processing was due to a negative correlation between psychopathic traits 
and neural reactivity to food stimuli. Therefore, it is possible that, in accordance with Cope and 
Vincent’s reports, that psychopathic traits may predispose individuals to addiction by a 
compensatory decrease in non-drug reward-reactivity that is more severe than the abnormal 
drug-cue reactivity in psychopaths.  
 However, the interaction we observed demonstrated that as highly psychopathic 
individuals continue to use an addictive substance, they may start to exhibit the abnormal drug-
stimulus response identified by Cope et al (2014) and Vincent et al (2017). Therefore, highly 
psychopathic individuals may exhibit a decreased response to drug-related stimuli, regardless of 
the control condition utilized with increasing levels of substance use.  




 What is interesting is that we observed another interaction effect, occurring between 
psychopathic traits, substance use severity, and variant of substance dependence: psychological 
vs physiological dependence. Essentially, the psychopathy main effect and psychopathy*use 
interaction effects on drug > food processing within corticolimbic regions were only observed 
within psychologically-dependent participants, while no significant contribution of psychopathic 
traits was observed among physiologically-dependent participants. The sum of this research has 
implications for our understanding of the effect of psychopathic traits on drug-stimulus 
processing in the brain, as well as the comorbidity between psychopathy and drug addiction.  
As psychopathic traits were associated with a sensitized neural processing bias towards 
drug-related stimuli, particularly in psychologically-dependent participants, it is possible that 
psychopathic traits may potentially accelerate the one’s transition through the addiction severity 
spectrum, essentially accelerating one’s transition from impulsive and substance-independent 
substance use to an addiction. This could explain why psychopathic traits are more abundant in 
individuals with a substance dependent disorder. However, psychopathic traits were indifferent 
in number between psychologically- and physiologically-dependent participants. Moreover, if 
psychopathic traits only sensitized the neural processing bias towards drug-related stimuli, one 
might expect that increasingly psychopathic individuals would be more likely to be 
physiologically-dependent to a substance, and that psychopathic traits would have been greater 
among physiologically- compared to psychologically-dependent participants. This was not the 
case, and the interaction between psychopathic traits and substance use severity in 
psychologically-dependent participants may be the key in understanding this phenomenon. It is 
possible that psychopathic traits may sensitize the neural processing bias, which may lead to a 
psychological dependence to the substance at an accelerated and more aggressive rate. With an 




ever-increasing usage pattern, highly psychopathic individuals may show a premature 
desensitization of drug-related incentive salience leading to a dampening of the neural processing 
bias in highly psychopathic psychologically-dependent individuals. Therefore, psychopathic 
individuals may be psychologically-dependent to a substance for a longer period before 
eventually ceasing use and experiencing physiological-dependence symptoms, such as 
withdrawal. Subsequently, physiologically-dependent participants, regardless of high or low 
level of psychopathy or history of substance use, would be all similar in terms of neural 
processing bias towards drug-related reward, and potentially all similar in terms of addiction-
severity in this stage of the addiction spectrum.  
These results also have implications for understanding individual differences in 
predisposition to develop an addiction. Obviously, these results warrant further investigation in 
how traits characterizing psychopathy, such as impulsivity, reward sensitivity, abnormal 
empathy and callousness, affect neural processing abnormalities and transitions through 
addiction in non-offender and non-psychopathic populations. Moreover, these results may also 
warrant investigation into the extent that such traits, and their underlying neurological 
abnormalities, predict one’s transition from voluntary to compulsive drug use, and the experience 
of the three-stages of addiction, development of neural processing biases, and prognoses in terms 
of treatment. To elaborate, psychopathic individuals exhibit not only a behavioral sensitivity to 
rewarding stimuli, but also an enhanced dopaminergic reward response within the mesolimbic 
dopaminergic tract in response to rewarding cues (Bjork et al., 2012). In addition, psychopathic 
traits have been associated with a sensitized reward-response to amphetamine (Buckholtz et al., 
2010). However, our analyses demonstrated Factor 1 traits were the more influential 
constellation of psychopathic traits in drug > food processing, and Buckholtz et al. (2010) 




demonstrated that Factor 2 traits were the most influential in this abnormal dopamine response, 
demonstrating contrasting phenomena. However, one must question the effect of such a 
sensitized dopaminergic response to rewards, drug rewards in particular, on the development of 
neural processing abnormalities, and what effect this would have on one’s transition from non-
dependence to dependence to a substance, and furthermore, the escalation from psychological to 
physiological dependence. It is possible that this sensitized dopaminergic response may be a 
strong underlying factor that may sensitized neural processing biases in psychologically-
dependent subjects, which may exacerbate the severity of their addictive disorder by potentially 
accelerating the transition from psychological to physiological dependence. Therefore, 
individuals with this heightened dopamine responsivity may be at an increased risk, regardless of 
the level of psychopathy, to develop an addiction.  
Towards a new diagnostic method and categories 
 Finally, this body of research, including prior studies on the comorbidity between 
psychopathy and addiction, the relationship between psychopathic traits and neural processing 
abnormalities, and the relationship between psychopathic traits and dopaminergic reward to 
drugs of abuse, warrant the investigation into whether these are two distinct disorder that should 
have their own categories (as is currently the case), or whether a new diagnostic method should 
consider these a combined and special category in and of itself. Using this addiction-related 
neurocognitive abnormality that is, itself, affected by psychopathic traits, we may be able to 
characterize new and more accurate forms of addiction that may yield more effective in 
treatment and prevention of these disorder.  
There has been a recent call for new manners through which to characterize and diagnose 
mental disorders, including SUDs, based on observable behavioral and neurobiological features. 




Such an example is the National Institute of Health’s (NIH) Research Domain Criteria (RDoC) 
project, which is part of the NIH’s Strategic Plan for Research (NIH, 2015). The RDoC project 
identifies complex behaviors and their underlying molecular, cellular, and neural underpinnings 
in order to create new flexible and increasingly accurate diagnostic categories that can yield 
more effective treatment and preventative methods.  
Using an RDoC approach, we may be able to categorize individuals based on a broader 
range of dysfunctions that encompass both behavioral and neurological. This could render 
diagnostic categories more specific, accurate and effective in identification and treatment of 
addictive disorders, as well as associated externalizing disorder like psychopathy. Considering 
psychopathic traits are highly abundant in populations with SUDs, and psychopathic traits play a 
significant role in addiction-related dysfunctions, targeting these dysfunctions in diagnostics may 
help identify the psychopathy-addiction category that would be separate from less-psychopathic-
addiction groups and non-addicted psychopathic groups. Neural processing of drug- and non-
drug rewards may be used as a marker for the severity of one’s addiction, and following a 
separation of the groups based on this neural processing bias, groups could be further subdivided 
based on the level of psychopathy and substance use; the influence of these factors on this bias; 
and differences in a variety of other factors that could have incremental value to the 
categorization.  
Subjects within these novel categories would then be recommended for treatments that 
were tailored to target the specific dysfunctions characterizing the group that have previously 
been rendering treatment protocols limited in their effectiveness. For instance, proportions of the 
SUD population with a high level of psychopathic traits may have been treatment resistant due to 
confounding factors that are not addressed in substance abuse treatment. For instance, 




psychopathic traits have been considered highly treatment resistant, and the implication of that 
clinically-relevant limitation on the treatment of other concomitant dysfunctions remains 
unknown. Creating new, and more representative categories, based on both neurological 
dysfunctions and behavioural abnormalities, would help create highly tailored treatment 
methods, which may be able to effectively reduce substance misuse, psychopathic tendencies, 
and the psychosocial impact of these factors.  
However, an important issue must also be addressed when attempting to create this novel 
diagnostic model. In the current thesis, and studies alike, standard parametric data analyses may 
solve for high effect sizes that are statistically insignificant, particularly among small samples 
sizes. As a result, research-based diagnostic models may overlook important neural features that 
may help distinguish between psychopathological categories by ignoring statistically 
insignificant, yet clinically significant, underlying neural features, and committing a Type II 
error. When considering the data for the current thesis, limitations in terms of sample and group 
sizes may have precluded the ability to achieve significant effects, yet effect sizes (including 
Pearson r correlations, variance explained, and t values) would still be large according to the 
literature (Cohen, 1988, 1992). The current thesis compensated for this fact by interpreting 
results nearly reaching or marginally significant, with consideration of the risk of Type I  errors.  
Similarly, studies with similar sample sizes that present large effect sizes with a lack of statistical 
significance should include emphases on the clinical significance of the results to the 
understanding of psychopathology. However, researchers must also be careful not to over-
interpret null effects, and risk making Type I errors for future research to build upon. Therefore, 
one must consider the importance of clinical versus statistical significance, and experts should 




work to establish standards that both reduce the risk of Type I False Positive errors, but also 
emphasize the importance of clinical yet statistically insignificant findings.  
Future studies 
 There are several frontiers for future studies to investigate based on the presented body of 
research. While psychopathic traits and substance use severity were certainly influential, there 
could be several other variables that could be influential as well, including gender, ethnicity, as 
well as the severity of physiological and psychological dependence. Future studies should 
investigate the impact of these factors, as well as the impact of the severity of withdrawal, 
substance-use-related behavioral dysfunctions, and the severity of tolerance on this neural 
processing bias, and how these factors interact with psychopathic traits and substance use 
severity.  
 In addition, research should focus on understanding what structural and functional neural 
mechanisms underlie not only this neural processing bias, but also differences between 
psychologically- and physiologically-dependent participants, and what structural correlates to 
psychopathic traits may be an explanatory factor for psychopathy’s role in neural processing 
abnormalities in addiction. Psychopathic traits are associated with a number of structural 
abnormalities, including grey matter alterations to corticolimbic regions (Boccardi et al., 2013; 
Cope et al., 2012, 2014b; de Oliveira-Souza et al., 2008; Ermer et al., 2012; Hyde et al., 2014; 
Yang et al., 2009, 2010); white matter alterations within the uncinate fasciculus, a white matter 
tract connecting fronto-cortical within mesolimbic regions (Sobhani, Baker, Martin, Tuvblad, & 
Aziz-Zadeh, 2015; Wolf et al., 2015); and with altered resting-state network connectivity 
(Philippi et al., 2015). These could all be underlying explanatory factors for the effect of 




psychopathic traits on drug-stimulus processing and should be carefully examined as means of 
further understanding the comorbidity between psychopathy and addiction.  
 Moreover, understanding the structural and functional neural underpinnings for various 
levels of addiction, and how individual differences (i.e., psychopathic traits, impulsivity, 
substance use history) moderate these neural underpinnings, could help create a multi-modal 
statistical model to use as a research-driven (e.g., RDoC) diagnostic tool. Neuroimaging research 
has become increasingly aware of the limitations of individual neuroimaging metrics (i.e., 
BOLD-signal based analyses, Positron-Emission Tomography, Electroencephalogram; Coltheart, 
2006; Stufflebeam & Rosen, 2007). For instance, BOLD-signal neuroimaging contrasts (used in 
the current study) have the limitation of being is highly sensitive to signal loss at orbitofrontal 
and temporal regions near the skull, as well as limitations in temporal resolution (Detre & Wang, 
2002). However, experts have noted that multi-modal approaches may exploit differences 
obtained from various neuroimaging strategies and offer a more convergent and complete model 
to use in diagnostic and research-based contexts (Gouws, Woods, Millman, Morland, & Green, 
2009; Stufflebeam & Rosen, 2007). Future studies should assess the multi-modal statistical 
models that best represent various levels of addiction, that best separates various levels of 
addiction, and best implicates individual differences and non-neuroimaging-related factors into 
the model.  
Furthermore, another future direction could be utilized as a possible means of finding 
clinically-significant neural features that may appear insignificant according to theory-based data 
analysis strategies. Researchers should assess neurocognitive abnormalities in addiction using 
big-data data-driven computational approaches, which would have the benefit of identifying 
patterns in a complete post-hoc and unbiased manner from typical theory-driven analytical 




techniques (Mazzochi, 2015). Typical-theory driven approaches, such as General-Linear Model 
analyses, compare the data to what would be expected from the Gaussian normal distribution, 
and are based on preconceived hypotheses on the results of the analyses (Kim, 2008; Mazzochi, 
2015). Other approaches, such as Independent-Component Analysis (McKeown et al., 1998) and 
Principal Component Analysis (Friston, 1994), have the added benefit to typical data analysis 
techniques of identifying interesting, and more importantly, clinically-significant findings that 
could be used in these research-driven diagnostic model-developments (Kim, 2008). Conducting 
these data-driven analyses on exceptionally large datasets that abate the need for a Gaussian 
distribution-comparison would be useful for the development of new thresholds that could be 
used for future theory-driven research that will ensure the publication of both statistically sound 
and clinically-significant results, while also reducing the risk of Type I and Type II errors. These 
data-driven, and reconceptualized theory-driven, study protocols could be targeted towards 
neurocognitive abnormalities in addiction and help create new research-driven diagnostic 
categories while also considering the role of individual differences, such as psychopathic traits 
and drug use history.   
Finally, an important distinction between the DSM-IV-TR substance dependence 
diagnostic criteria, and criteria for DSM-5 SUD, is the implication of craving. Craving is 
considered one of the three-stages of the addiction cycle that is considered to increase with 
increasing levels and history of substance use and periods of withdrawal (Koob & Le Moal, 
1997, 2005, 2008a, 2008b; Koob & Volkow, 2010; Robinson & Berridge, 1993, 2000). While 
our separation of psychological and physiological dependence was appropriate for DSM-IV-TR 
operationalizations of SUDs, studies looking to separate levels of addiction should also 
investigate whether craving fits into either physiological or psychological substance dependence, 




or perhaps both. Furthermore, studies should assess whether the inclusion of craving has an 
interaction with both psychopathic traits and substance use severity, and whether it could further 
separate physiological and psychological dependence based on this neural processing bias. This 
initiative would be another attempt to empirically demonstrate, in human subjects, whether the i-
RISA model and the three-stage model of addiction are, in fact, as accurate or provide 
incremental validity to DSM operationalizations of SUDs and could further improve novel 
categorizations of these psychopathological disorders for ameliorated clinical applications.  
Conclusion 
 We successfully furthered our understanding of not only neural dysfunctions in substance 
dependence, but also how psychopathic traits modulate these neural dysfunctions as a means of 
facilitating a SUD. By sensitizing neural processing biases towards drug-related stimuli, 
psychopathic traits may be a predisposing to the development of a psychological substance 
dependence disorder characterized by a neural preference towards drug-related rewards 
compared to non-drug rewards. This effect may lead to such individuals eventually developing a 
physiological substance dependence disorder, which would be characterized by severe 
behavioral dysfunctions and the highest magnitude of this neural processing bias towards drug-
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